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Abstract: Short-term patient and graft outcomes continue to improve after kidney and liver transplantation, with 1-year survival
rates over 80%; however, improving longer-term outcomes remains a challenge. Improving the function of grafts and health of re-
cipients would not only enhance quality and length of life, but would also reduce the need for retransplantation, and thus increase
the number of organs available for transplant. The clinical transplant community needs to identify and manage those patient mod-
ifiable factors, to decrease the risk of graft failure, and improve longer-term outcomes.
COMMIT was formed in 2015 and is composed of 20 leading kidney and liver transplant specialists from 9 countries across
Europe. The group’s remit is to provide expert guidance for the long-termmanagement of kidney and liver transplant patients, with
the aim of improving outcomes by minimizing modifiable risks associated with poor graft and patient survival posttransplant.
The objective of this supplement is to provide specific, practical recommendations, through the discussion of current evidence and
best practice, for themanagement of modifiable risks in those kidney and liver transplant patients who have survived the first post-
operative year. In addition, the provision of a checklist increases the clinical utility and accessibility of these recommendations, by
offering a systematic and efficient way to implement screening and monitoring of modifiable risks in the clinical setting.
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S2 Transplantation ■ April 2017 ■ Volume 101 ■ Number 4 www.transplantjournal.comSolid organ transplantation has evolved from an experi-mental procedure to an established treatment option
for many types of end-stage organ failure. Both patient and
graft outcomes are continuing to improve, and 1-year patient
and graft survival currently exceed 80%.1,2 However, sur-
vival rates gradually decline over the long term. In kidney
transplant, 5- and 10-year graft survival rates in Europe are
77% and 56%, and for liver transplant, 64% and 54%
(Figures 1 and 2).3,4Although most European countries have seen an increase
in both living and deceased donation, transplantation is not
available to all who would benefit from the procedure, and
there is considerable morbidity and mortality for those
listed for transplant.6 Therefore, maximizing long-term
graft survival and reducing the need for retransplantation
is paramount, not only in improving outcomes for the re-
cipients but also for those awaiting a graft. The improve-
ment in outcomes is predominantly due to reduction in
FIGURE 1. 1- to 10-year graft and patient survival rates after kidney transplantation.*1-year and cumulative 5- and 10-year age-adjusted kid-
ney graft survival rates calculated for 2005 to 2008 by period analysis; †Survival probabilities were adjusted for age, sex and cause of end-stage
renal disease (data shown in figure for period 2004-2008); ‡Data from 2007 to 2011 period not shown in figure. Figure based on data from
Gondos 2013 and Kramer 2016.3,5
© 2017 Wolters Kluwer Neuberger et al S3early graft loss and patient death, better surgical and anes-
thetic skills, technological innovations, improved donor
and recipient management, and the advent of newer and
more effective immunosuppressive agents.7 Despite the im-
provement in survival rates, attention is now becomingFIGURE 2. 1- to 10-year graft and patient survival rates in liver transpla
Registry: www.eltr.org/Evolution-of-LTs-in-Europe.html4 (Accessed Julymore focused on improving longer-term outcomes beyond
the first year posttransplant.
Posttransplantation care requires involvement from multi-
disciplinary healthcare professionals (HCPs) who must work
collaboratively with the patient, their family, and the healthcarentation. Reprinted with permission of the European Liver Transplant
2016).
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volves the consideration ofmany factors and balancing the need
for immunosuppressionwith the associated risks. In addition to
the direct and indirect consequences of immunosuppression,
a multitude of risk factors influence patient and graft sur-
vival. Some risk factors may be present before transplanta-
tion (such as cardiovascular disease (CVD) seen especially
in kidney transplant recipients), and other factors, such as
donor age, cannot be modified.8,9 However, some risk fac-
tors have the potential to be modified or mitigated posttrans-
plantation to improve outcomes, including behavioral risk
factors, such as medication adherence.10-12
The Consensus On Managing Modifiable risk In Trans-
plantation (COMMIT) group was convened to provide
practical recommendations for the identification and man-
agement of modifiable risk factors to maximize the life of
the graft and patient after kidney and liver transplant.
Modifiable Risk Factors for Graft
Loss Posttransplantation
Although solid organ transplantation improves both the
quality and quantity of life of the recipient, the survival is less
than an age-matched cohort from the general population. A
study in the United Kingdom of adult liver allograft recipi-
ents, who had survived the first postoperative year, showed
the average number of life-years lost was 7.7 years; those
who had their transplants at a younger age (17-34 years)
had a far greater loss of life-years than those who had their
transplant later (≥35 years), and women had fewer life-
years lost than men.13,14 The main causes of death included
cardiac problems, malignancy, and infection, and causes of
graft failure included recurrent disease and chronic rejec-
tion.15,16 In a retrospective review of 4483 adult primary
liver transplant recipients, major causes of death were malig-
nancy (30.6%), multisystem failure (10%), infection (9.8%),
graft failure (9.8%), and CVD (8.7%).17
El-Agroudy et al15 found the main causes of death in kid-
ney allograft recipients were infections (35.6%), CVD
(17.6%), liver disease (11.4%), and malignancy (6.1%). Of
nearly 1600 kidney recipients in Japan, Shimmura et al16
found the main causes of death with a functioning graft wereFIGURE 3. Causes of late graft loss in kidney transplant recipients. Figur
Lefaucheur 2010, Koenig 2016, Valenzuela 2013, Siedlecki 2011 and Pinfection (24%), stroke (17%), CVD (16%), malignancy
(15%), and liver failure (12%).
Graft loss has been attributed to both immunological and
nonimmunological factors in kidney and liver transplant re-
cipients (Figures 3 and 4).
Preoperative, perioperative, and postoperative factorsmay
impact long-term outcomes; these include donor and organ
factors as well as logistic factors. For kidney transplantation,
these include early ischemic injury, acute allograft rejection,
and delayed graft function (DGF). For liver transplanta-
tion, early allograft dysfunction (EAD), prolonged cold ische-
mia times and use of steatotic livers and organs from donation
after cardiac death (DCD) donors may contribute to reduced
graft and patient survival.32-34
In both kidney and liver transplant recipients, modifiable
risk factors for graft failure over the longer term include is-
sues related to immunosuppression, such as nonadherence,35
underimmunosuppression,36 toxicity and adverse effects re-
lated to immunosuppression,37 and high intrapatient variabil-
ity (IPV) in immunosuppressive exposure.38 The development
of de novo donor-specific antibodies (DSAs) is also considered
to be amodifiable risk factor, and has been strongly associated
with nonadherence to immunosuppression in kidney trans-
plant recipients.20 However, knowledge of the pathological
impact of DSAs is still evolving, particularly with regard to
the impact of DSAs postliver transplantation.39-41
Furthermore, patient survival can be improved by atten-
tion to modifiable risk factors for CVD and cerebrovascular
disease, some infections and some cancers.34 The develop-
ment of new-onset diabetes posttransplant (NODAT) is also
associated with reduced patient and graft survival, as well
as an increased risk of infections and CVD.42 This list of risk
factors is not exhaustive. Other factors that may have an im-
pact on graft or patient survival include recurrence of initial
disease.34 Although there is little to be done regarding the
nonmodifiable risk factors of graft failure, better screening
and management of modifiable risk factors could improve
long-term survival rates if integrated into routine clinical
practice. Each section in this guidance document includes a
review of the problem to be addressed, a summary of the lit-
erature and current clinical practice.e based on data from Jevnikar 2008, Pazhayattil 2014, Sellarés 2012,
uttarajappa 2012.18-25
FIGURE 4. Causes of late allograft loss in liver transplant recipients. Diabetes, hypertension, hyperlipidemia, high variability and nonadherence
to immunosuppressive agents are modifiable risk factors. Figure based on data from Hübscher 2011, Bekker 2009, O’Leary 2014, Supelana
2014, Charlton 2013 and Kamar 2008.26-31
© 2017 Wolters Kluwer Neuberger et al S5Existing Clinical Guidance for Long-Term
Management in Transplantation
There are several national and international guidelines
outlining approaches to improve both kidney and liver graft
outcomes. Implementation of some of the recommendations
has been shown to improve outcomes; for example, imple-
mentation of the predefined donor management goals defined
by the United Network for Organ Sharing (UNOS) has re-
sulted in a significant decrease in the incidence of DGF in those
cases where the donor management goals were met.43 In addi-
tion, cardiovascular prediction models and risk calculators to
predict the risk of developing cardiovascular complications
posttransplant are being introduced in the clinic and their
use may allow introduction of targeted interventions that will
reduce morbidity and mortality.44 However, comprehensive,
standardized methods to identify, screen and manage poten-
tially reversible risk factors for graft failure and patient death
are lacking in many of the current guidelines, as discussed be-
low. Furthermore, with the increasing number of surviving al-
lograft recipients, many are being followed in nontransplant
centers and by HCPs who may not be as familiar with cur-
rent best practice as those working in transplant units.
Objectives and Aims of COMMIT
COMMITwas formed in 2015 to provide expert practical
guidance for the long-term management of kidney and liver
transplant patients, with the aim of improving outcomes by
minimizing modifiable risks of poor graft and patient sur-
vival posttransplant. The COMMIT expert group comprises
20 leading kidney and liver transplant specialists from 9
countries across Europe.
Objectives
The group's objectives are to develop specific, practical re-
commendations that focus on the management of modifiablerisk in those kidney and liver transplant patients who have
survived the first postoperative year, including some pre-
transplantation and peritransplantation considerations.
Target Audience
The prime target audience are HCPs, including medical
staff, nurses and pharmacists caring for allograft recipients
outside transplant units, and junior professionals working
in transplant units, although the recommendationswill be rel-
evant to all those involved in the care of transplant recipients.
Recommendations
The recommendations are intended to complement, rather
than replace, local guidelines. Therefore, specific recommen-
dations have not been provided on immunosuppression reg-
imens or the investigation and management of abnormal
graft function.
In this guidance document, we discuss each of the identi-
fied modifiable risk factors (Table 1) for both kidney and
liver transplantation. Each section begins with a discussion
of the evidence and current best practice related to the
management of the risk factor, followed by a separate set of
specific recommendations for each organ. To increase the
clinical utility and accessibility of the recommendations, we
have created a checklist (Appendices 2 and 3) that could be
used as an aide-memoire for the professionals looking after
these patients. Importantly, the checklist provides a
systematic and efficient way to implement screening and
monitoring of risk in the clinical setting.
It is important to stress that the recommendations are
sometimes broad, because all treatment and interventions
must be tailored to the individual transplant recipient. As
mentioned, patient and graft outcomes will depend on
many factors, including recipient age, sex, lifestyle,
TABLE 1.
Major modifiable risk factors for graft loss
Nonadherence
Intrapatient variability in immunosuppressive exposure
Underimmunosuppression/overminimization of immunosuppression
Adverse effects related to immunosuppression
DSAs
Early ischemic injury and DGF (kidney)/EAD and nonanastomotic
biliary strictures (liver)
Cardiovascular and metabolic complications
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and surgical factors may also have a significant impact
on outcomes. Nevertheless, we believe that formalized
screening and management of modifiable risk factors in
all patients after the first year of transplantation will lead
to marked improvement in long-term outcomes. Specific
recommendations have not been provided on immunosup-
pression regimens or the investigation and management of
abnormal graft function.
General health recommendations, such as smoking cessa-
tion and avoidance of excessive alcohol consumption, have
not been discussed in detail, because these should form part
of every clinical appointment.
These guidelines focus on major modifiable risk factors
that improve long-term outcomes after liver and kidney
transplantation in adults. However, 2 aspects of general care
merit mention: immunization, which plays an important role
in reducing the risk of some infections; the response to immu-
nization may be blunted and live and attenuated vaccines
avoided.45 Sexual health is also important, and patients
should be advised about the teratogenicity of some immuno-
suppressive agents and the need to consider the impact of
pregnancy both on the risk of rejection and the pharmacoki-
netic changes of drug metabolism.46-48
We have also notmade recommendations on the frequency
of follow-up after the first year because this will depend on
many factors, including the clinical status of the patient, co-
morbidities, and graft function. If the patient is stable and
with good graft function and over 1 year posttransplant, then
most centers recommend assessing the patient every 3months.
If the patient becomes unwell, graft function deteriorates,
changes medication, then the review should be more fre-
quent. If the immunosuppression regimen is modified, then
therapeutic drug monitoring and patient assessment should
be done more frequently. If the immunosuppression is
discontinued, drastically reduced or other drugs that affect
metabolism of the immunosuppressive agents are prescribed,
then the drugs and graft should be monitored more fre-
quently, and dailymonitoringmay be indicated.Hospitalized
allograft recipients will usually have drug levels of calcine-
urin inhibitors (CNIs) or mammalian target of rapamycin in-
hibitors (mTORi) checked daily.
METHODS
The COMMIT program featured 2 organ-specific work-
ing groups (kidney and liver). Eachworking groupwas further
divided intoworkstreams to develop the recommendations for
each of the modifiable risk factors in parallel.
Aworkstream lead was appointed to oversee the develop-
ment of the practical recommendations and to facilitateconsensus within the respective workstreams. All members
of the COMMIT program reviewed and provided feedback
on all sections of the guidance report as part of a Delphi
study, as described below.
Literature Review
A literature review was conducted to gain an understand-
ing of current posttransplant clinical practices and to identify
the key gaps in the available guidance related to the practical
management of modifiable risk factors in posttransplanta-
tion care. MEDLINE and Google Scholar databases, and re-
sources from international transplant societies were searched
for kidney and liver transplantation guidelines using varying
search terms including kidney transplant guidelines, liver
transplant guidelines, kidney transplant recommendations,
liver transplant recommendations.
The original search was conducted between August 7,
2015, and September 10, 2015, and was restricted to English
language articles; the guidelines included were published be-
tween 1999 and 2015. The search results were filtered ac-
cording to relevance for kidney or liver transplantation and
for guidance posttransplantation. A summary document, or
“concept paper,” was created based on the results of the
literature review to focus and inform initial discussions
on the concept and content of the recommendations. Sub-
sequent literature reviews were conducted in early 2016
within the respective workstreams to develop and support
the practical recommendations.
Development of Practical Recommendations Using a
Modified Delphi Approach
A modified Delphi approach (Figure 5) was used to reach
agreement and validate the practical clinical recom-
mendations. The qualitative and interactive Delphi approach
has been described previously.49 A total of 18members of the
COMMIT group participated in the first online Delphi-
like survey (November 2015). The first survey was used
to explore the modifiable risk factors that lead to graft loss
in clinical practice, and prioritize them for discussion in the
guidance document. Furthermore, the survey gave the op-
portunity for the group to comment on those risk factors
or topics that had not been addressed. This informed the
development of the concept paper. A preliminary meeting
of all authors was held on December 9, 2015, to discuss the
results of the literature review and the Delphi-like online
survey. Feedback and discussions from this meeting were
collated into an initial discussion document, which formed
the basis of the second Delphi-like survey (May 2016). In
the second survey, COMMIT group members were asked
to review the first draft of the guidance report, and to state
their level of alignment with the content included. If not
aligned, members were invited to provide reasons and
supporting evidence for consideration for inclusion in the
guidance report. The results of the second Delphi-like
survey included responses from 18 COMMIT members.
A second COMMITmeeting was held on June 22, 2016, to
discuss the practical recommendations. A third Delphi-like
survey included all 20 members of the group and was
conducted in October 2016. The survey focused on the
group's satisfaction with the recommendations that had
been made, the checklist that had been developed, and fi-
nal agreement on the guidance report.
FIGURE 5. Modified Delphi approach.
© 2017 Wolters Kluwer Neuberger et al S7Practical recommendation statements achieving 100%
agreement were included in the final guidance document.
The evidence supporting each recommendation was evalu-
ated and graded according to the Oxford Centre for
Evidence-Based Medicine (OCEBM) system (see Appendix 1).50
The evidence is ranked on a hierarchy with the strongest best
evidence (such as a systematic review of randomised trials)
assigned level 1 and evidence based solely on understanding
of known mechanisms assigned level 5 (lowest grade). This
enables clinicians to understand the strength of the evi-
dence.50 The recommendations were proposed by the section
authors and approved by all authors.
Limitations of Methodology
The use of any evidence ranking system, such as the
OCEBM, for patient management recommendations should
be carried out with clinical judgment as forethought.50 Al-
though these recommendations did achieve an acceptable level
of agreement (100%) using the Delphi-like approach, this
method identifies current medical opinion, and is not an alter-
native to rigorous clinical trials, where evidence is lacking.49
NONADHERENCE TO IMMUNOSUPPRESSIVE
AGENTS AS A MODIFIABLE RISK FACTOR FOR
POOR OUTCOMES IN LIVER AND KIDNEY
TRANSPLANTATION
Problem to be Addressed
Transplantation offers patients with end-stage liver or kid-
ney disease improved quality of life and longer survival.51,52However, transplant recipients need to adhere to complex
therapeutic regimens often including 1 or more immuno-
suppressive agents and other medications to prevent or
treat comorbidities.10-12
Historically, research relating to adherence has been fo-
cused on adherence to medication. However, it is now recog-
nized that adherence includes a broad range of health-related
behaviors that need to be considered in addition to taking
prescribed medication, such as the relationship between the
patient and healthcare provider.53,54 In addressing some of
these complexities, The World Health Organization defines
nonadherence to a long-term therapy as “the extent to which
a person’s behavior—taking medication, following a diet,
and/or executing lifestyle changes, corresponds with agreed
recommendations from a healthcare provider.”53
Nonadherence to a treatment regimen can entail not taking
a dose, irregularity of drug taking, drug holidays, dose reduc-
tion, or discontinuation of drug taking.55,56 Patients have to
manage complex and sometimes changing medication sched-
ules, deal with emotions and indebtedness towards clinicians
and their organ donor, and cope with side effects of drugs.57
Nonadherence can also be intentional or nonintentional.58
Nonadherent transplant recipients tend to have less control
over their lives, can be more forgetful, miss more doses when
diverted from a daily routine, and skip doses, especially when
short of money.59 These nonadherent patients can also feel
that immunosuppressive regimens are a disruption to their
lives, or are not necessary at all.59 In a study by Greenstein
et al,60 3 distinct groups of noncompliers were identified
TABLE 2.
Multilevel risk factors for nonadherence to
immunosuppressive regimens55,58,62,73-76
Risk factor Examples
Sociodemographic factors • Adolescence, senior patient age
(eg, when cognitively impaired)
• Lack of social support
• Non-white race
Patient-related factors • Previous nonadherence
• Disturbing side-effects
• Barriers: busy lifestyle, interruption
of daily routine
• Forgetfulness
• Inadequate health beliefs
• History of substance abuse
Treatment-related factors • Higher complexity and longer duration of the
drug regimen, number of prescribed pills
• Taste and size of the pill
Condition-related factors • Depressive symptomatology
Healthcare teams and
systems factors
• Lack of adherence assessment as part of
regular transplant follow-up
• Lack of adherence support as part of
transplant follow-up
• Lack of coverage of immunosuppressive drugs
• HCPs not trained in behavioral assessment
and interventions, or adequate
communication style
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pliers, patients who felt invulnerable, and decisive noncompliers.
Each of these groups required different interventions.55,60
There are several studies on the recipients’ perspectives of
medicine-taking. A study of 113 adult kidney transplant re-
cipients found that there were 3 patient attitudes towards
medication and adherence: “confident and accurate,” “con-
cerned and vigilant,” and “appearance orientated and asser-
tive.”54 However, the group discovered no significant
association between attitudes and self-reported nonadher-
ence.54 Massey et al61 found that in kidney transplant re-
cipients, despite reporting a high degree of perceived
necessity and had relatively few concerns about their im-
munosuppressive regimen, nonadherence increased signif-
icantly over a period of 18 months. The group concluded
that beliefs about immunosuppressive medication and ad-
herence in kidney transplantation were not related in
this study.61
Variability in measurement modalities, operational defini-
tions, and sampling methods makes comparisons between
nonadherence studies challenging; however, the evidence
points to a high level of nonadherence to immunosuppression
posttransplant (approximately 22-68%) across the transplant
continuum.35,62-64 It has been established that posttransplant
nonadherence to immunosuppressive regimens is an indepen-
dent risk factor for poor clinical outcomes.10-12
In liver transplantation, a retrospective study of 359 trans-
plant recipients showed that low adherence to treatment dur-
ing the first 6 to 18months posttransplant led to a higher risk
of graft loss.35 Nonadherence predicted acute rejection (odds
ratio [OR], 4.95; 95% confidence interval [CI], 1.6-14.7)
during a 5-year follow-up period.65 Most importantly, non-
adherence negatively impacted on graft and patient survival
after liver transplantation.66 A 2006 retrospective audit
of the Scottish Liver Transplant Unit’s database estimated
nonadherence to be responsible for 1 in 10 deaths in liver
transplant recipients.67
A meta-analysis by Dew et al62 demonstrated the rate of
nonadherence to have been more common in kidney trans-
plant patients compared to recipients of other solid organs,
including liver, heart and lung, with a rate of 36 cases per
100 patients per year in the kidney group. Furthermore, it
has been reported that nonadherence may be a contributing
factor to graft loss in 36% of kidney transplant recipients.55
Nonadherence is also an independent risk factor for the de-
velopment of de novo DSAs and higher rates of graft failure
in kidney transplantation.20 Sellarés et al20 demonstrated a di-
rect link between the development of DSAs, nonadherence to
treatment and graft failure.Of the 315 patients in this prospec-
tive study, concerns about nonadherence were recorded in
26 patients. Grafts failed in 19 of these nonadherent patients,
with a total of 17 reported as rejection-related failures.
Nonadherence pretransplant is a predictor of nonadher-
ence posttransplant.66 A prospective study of 141 lung, heart,
and liver transplant patients showed that pretransplant nonad-
herence was a predictor of poor adherence posttransplant
(OR, 7.9; 95% CI, 2.35-26.8).68 This finding was supported
by a larger prospective nationwide cohort study of 1505 renal,
liver, lung and heart transplant patients (OR, 3.10; 95% CI,
2.29-4.21).66 Pretransplant self-reported nonadherence has
also been found to be a predictor of acute rejection (OR, 4.4;
95% CI, 1.18-16.16).68The large impact that nonadherence has on treatment ef-
fectiveness is reflected in poor patient health outcomes, and
increased healthcare costs.53 Data demonstrate that the
economic burden of nonadherence to immunosuppressive
regimens is substantial, although specific data for liver
transplantation are lacking.10 Using an economic model of
renal transplantation over a lifetime, Cleemput et al69
showed that quality-adjusted life years, a measure of disease
burden, was greater for adherent patients, than nonadherent
patients. The considerable financial impact of nonadherence
to immunosuppressive regimens is evidenced by the high
costs of kidney transplantation.70 Pinsky et al71 reported
that, 3 years after renal transplantation, a nonadherent pa-
tient, on average, generates US$ 12 840 higher medical costs
compared with a highly adherent patient.
This evidence indicates that reducing nonadherence has
the potential to significantly improve medium- and long-
term outcomes in organ transplantation. Understanding the
factors associated with nonadherence contributes to risk as-
sessment, and could aid the development of preventative
and remediating interventions.72
Multilevel Risk Factors for Nonadherence: Call for
Multilevel Adherence Interventions
Nonadherence is the result of many interacting factors,
and can be tackled at different levels of the healthcare sys-
tem.73 Established multilevel risk factors for nonadherence
include sociodemographic factors, treatment- and condition-
related factors, healthcare teams, and system-related fac-
tors.12 More information on these multilevel risk factors
can be found in Table 2. The relation between these factors
is complex: a meta-analysis of 147 studies in kidney, heart,
FIGURE 6. Identification of risk factors in nonadherent transplant recipients. Grey boxes represent methods of measurement/assessment of
nonadherence, and white boxes are warning signs for the nonadherent patient. Figure based on data from Prendergast 2010, Pabst 2015,
Denhaerynck 2005 and Dobbels 2010.55,77-79
TABLE 3.
Patient-level interventions for nonadherence to
immunosuppressive regimens55,82,83,86,93,95
Patient-level interventions Examples
Counseling/behavioral
interventions
• Training patients during inpatient recovery
on how to take medications
• Providing adherence reminders during
clinic visits
• Medication schedules
Psychological/affective
interventions
• Involving family
• Providing support with educational and
behavioral interventions
• Establishing support groups directed
at adherence
Educational/cognitive
interventions
• Providing printed medication instructions/clear
prescription instructions
• Individual patient/family teaching
Medical interventions • Simplified regimens, eg, monotherapy,
once-daily dosing or long-acting
parenteral administration
• Medication reminder cues, prefilled/easy-to-use
pill boxes, contingency plans for missed doses
• Clinicians need to be aware of concomitant
medications and focus on prescribing the
most essential medication
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plant recipients, found little correlation between nonadher-
ence and most patient psychosocial characteristics. Based
on this, the authors suggested a shift in focus towards
provider-related and system-related factors.62,73
Identification of Nonadherent Transplant Recipients
Accurate recognition of patients who are nonadherent is
often difficult, so effective tools for identifying at-risk patients
are very important.77 Some of the available tools/methods for
identifying nonadherent patients are shown in Figure 6.
Strategies for Managing Nonadherence
Identification of patients at risk for nonadherence could
be initiated by routinely and systematically assessing medi-
cation adherence as the “fifth vital sign” (integrated into
the electronic medical record) along the transplant contin-
uum. In the absence of sophisticated methods for assessing
nonadherence in daily clinical practice, such as electronic
monitoring, it is advisable to combine all the information
from available sources, such as self-reports, collateral re-
ports, pharmacy refill data and/or assays,80,81 to determine
at each clinical encounter whether patients are experiencing
issues with nonadherence.12
Once patients at risk of medication nonadherence are
identified, they can be targeted for more intensive, tailored
interventions. Implementation of these interventions should
be tailored to the barriers to drug adherence that have been
identified, or other targetable risk factors for nonadher-
ence.82,83 Transplant follow-up care based on principles of
chronic illness management, in which support for patient
self-management for adherence to an immunosuppressive
regimen is integrated, resulted in higher levels of adherence
and/or improved clinical and healthcare utilization parame-
ters in 2 renal transplant studies.84,85
Current practice focuses strongly on patient education.86
However, this approach has limited efficacy for improving
adherence, and is therefore best combined with counseling/
behavioral interventions and psychological/affective inter-
ventions.86,87 A randomized controlled trial (RCT) of 150
adult renal transplant patients found that 1-year behavioralcontract intervention significantly improved adherence to
immunosuppressant therapy.88 Table 3 highlights some patient-
level interventions for managing nonadherence to immuno-
suppressive regimens.82,86 A recently presented RCT that
tested the efficacy of a multidimensional, 6-month adherence-
enhancing intervention in heart, lung, and liver transplant re-
cipients showed a 16% increase in adherence at the end of
the intervention period, an effect that persisted during the
6-month wean-off phase. Moreover, the intervention group
had a 10% decrease in mortality over the 5-year follow-up
period (P = 0.18). The theory-based core and tailored inter-
vention consisted of electronic monitoring of adherence;
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ing printouts, goal setting, action planning and motivational
interviewing. Patients found to be nonadherent received a
high level of tailored adherence interventions.89
Motivational techniques are important in shaping medicine-
taking behaviors, and 1 approach is the use of electronic de-
vices. In a recent RCT, the effectiveness of wireless-enabled
pill bottles to promote immunosuppression adherence in
120 kidney transplant recipients was investigated. Patient ad-
herence was found to be significantly higher in groups using
notifications and customized reminders, compared with the
control group.90 Another study demonstrated an association
between electronic medication dispensers and higher adher-
ence in a group of renal transplantation patients.91
Adherence interventions can be delivered in one-to-one
sessions, group sessions or using (interactive) e-health technol-
ogy. One recent communication also reported the development
of an 18-minute consumer-driven video to deliver information
about the importance of medication adherence to patients.92
Future work should assess which intervention delivery mode
is most appropriate for diverse clinical contexts, from an effec-
tiveness, as well as from a health economic perspective.
Simplified drug regimens (eg, monotherapy, once-daily
dosing, long-acting parenteral administration), medication
reminder cues, the support of family and friends, contingency
plans for missed doses, and easy-to-use pill boxes are all
strategies for further limiting the unintentional form of non-
adherence.58,59,93 However, there is convincing evidence
that a simplified immunosuppressive regimen might benefit
all patients, regardless of their susceptibility to nonadher-
ence.83,93,94 The Adherence Measurement in Stable Renal
Transplant Patients Following Conversion From Prograf
to Advagraf (ADMIRAD) study demonstrated superior im-
plementation of the once-daily prolonged-release tacroli-
mus regimen over the twice-daily regimen in adult renal
patients treated with tacrolimus twice daily for at least
3 months before inclusion. The study highlighted that sim-
plification of the regimen reduced the patient’s pill burden
and also eliminated the evening dose, which is more likely
to be missed.95 The authors suggested that further research
should include investigation into the pharmacologic effect
of a patient skipping a single twice-daily dose, versus skip-
ping a single once-daily dose, to understand the impact of
dosing error with each regimen.95
Nonadherence increases among adolescents, young adults,
and with senior patient age, signifying that these patient sub-
groups may require specific attention.55,96-98 A study of 108
adult liver transplant patients examined the risk factors for
compliance with prednisolone treatment (as part of a double
or triple drug immunosuppressive regimen) and found that
age below 40 yearswas a significant risk factor for nonadher-
ence.99 Furthermore, Pinsky et al71 reported that adolescent
kidney transplant recipients aged 19 to 24 years were more
likely to demonstrate persistent nonadherence, than patients
aged 24 to 44 years. A particular concern is the risk of young
adults not recognizing their own nonadherence.100 These
nonadherent groups may profit from targeted education,
medication schedules, clear prescription instructions, and
simplified drug regimens. Reminder cues and prefilled pill
boxes might also be useful in these patient groups.55
Community-based young adult clinics can have a positive
impact on both medication and clinic adherence, and the socialaccountability in transition program has also shown promise
for improving adherence in younger transplant patients.97
In view of the existing data, it seems reasonable to suggest
that clinicians should routinely repeat keymessages to patients
at appropriate opportunities during posttransplantation
consultations (eg, highlighting the risks associated with
nonadherence to therapy). However, education alone may
not be sufficient and further interventions may be required
to modify a patient’s habits and behavior.86 In summary,
a combination of different interventions may be the most
effective strategy in enhancing patient self-management
and adherence to medication, and ultimately improving
outcomes posttransplant.80Recommendations for Managing Nonadherence in
Kidney Transplantation
1. Establish a “baseline” evaluation of medication adherence
at the time of listing for transplantation. (Level 3)
◯ Assess the patient’s previous ability to adhere to therapeutic
regimens
▪Tools include the Immunosuppressant TherapyAdherence
Scale (ITAS), simplified medication adherence question-
naire (SMAQ), Identification of Medication Adherence
Barriers Questionnaire (IMAB-Q) (https://www.uea.ac.
uk/pharmacy/research/imab-q/quest), Basel Assessment
of Adherence to Immunosuppressive Medication Scale
(BAASIS) questionnaire (available on request from the de-
velopers), or other validated self-report questionnaires
◯ Monitor the patient’s adherence to dialysis regimens
2. Nonadherence to an immunosuppressive regimen should be
assessed as the “fifth vital sign” at each clinical encounter post-
transplantation, based on evidence that it is a common and
independent risk factor for poor clinical outcomes. (Level 1)
3. Trough levels of relevant immunosuppressive drugs should
be regularly monitored (at least every 3 months when the
patient is stable) to assess for medication nonadherence; in
particular, unexplained high IPV and unexpected fluctua-
tions in immunosuppressant trough levels, despite a fixed
dose, should prompt a discussion with the patient about
the importance of drug adherence. (Level 1)
4. Maintain clinical awareness of direct risk indicators (eg,
drug concentrations, fluctuations (IPV) in drug levels, devel-
opment of de novo DSAs, prescription frequency, medica-
tion recall) and indirect risk factors (eg, patient’s mental
status, emotional/social status, adverse effects) of nonadher-
ence. (Level 3)
◯ Assess the patient’s social support network and emotional
and mental status (eg, using available questionnaires)
◯ Evaluate the prescription frequency of the proposed
immunosuppressive agent
◯ Use specific assays (eg, single-antibody bead assay) to mon-
itor the development of de novo DSAs (also refer to recom-
mendations in DSA section of this document)
▪ In the case of de novo DSAs, consider nonadherence
▪ If nonadherence is suspected, screen for de novo DSAs
5. Use different combined methods to objectively identify ad-
herence (eg, questionnaires, drug concentrations) during
the clinical visit. (Level 2)
◯ Discuss nonadherence with patients, and on indication, ask
patients to complete a questionnaire
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daily medications should be administered to improve adher-
ence. (Level 1)
7. In cases of adverse events, simplify/modify the immuno-
suppressive drug regimen as well as concomitant drugs.
(Level 1)
8. Discuss any suspicion of nonadherence openly and nonjudg-
mentally with the patient. (Level 5)
9. Together with the patient, identify his/her current barriers to
adherence and develop a personalized action plan with spe-
cific solutions, for example, pill boxes, (electronic) reminder
systems, education and psychological behavioral support.
(Level 5)
10. Together with the patient (and team), reassess the results of
the intervention(s) and adjust the strategy when indicated
(eg, residual nonadherence). (Level 5)
11. Patient-level interventions need to focus primarily on behav-
ioral change techniques, including training patients during
inpatient recovery on how to take medications, providing
adherence reminders during clinic visits, etc. Although im-
portant, patient education is only a small component of an
adherence intervention. Informationmust be given in aman-
ner appropriate for the patient. (Level 1)Recommendations for Managing Nonadherence in
Liver Transplantation
1. Establish a “baseline” evaluation of medication adherence
at the time of listing for transplantation. (Level 3)
◯ Assess the patient's previous ability to adhere to therapeutic
regimens
▪Tools include the Immunosuppressant TherapyAdherence
Scale (ITAS), simplified medication adherence question-
naire (SMAQ), Identification of Medication Adherence
Barriers Questionnaire (IMAB-Q) (https://www.uea.ac.uk/
pharmacy/research/imab-q/quest), Basel Assessment of Ad-
herence to Immunosuppressive Medication Scale (BAASIS)
questionnaire (available on request from the developers),
or other validated self-report questionnaires2. Nonadherence to an immunosuppressive regimen should be
assessed as the “fifth vital sign” at each clinical encounter
posttransplantation, based on evidence that it is a common
and independent risk factor for poor clinical outcomes.
(Level 1)
3. Trough levels of relevant immunosuppressive drugs should
be regularly monitored (at least every 3 months when the
patient is stable) to assess for medication nonadherence; in
particular, unexplained high IPV and unexpected fluctua-
tions in immunosuppressant trough levels, despite a fixed
dose, should prompt a discussion with the patient about
the importance of drug adherence. (Level 1)
4. Maintain clinical awareness of direct risk indicators (eg,
drug concentrations, fluctuations (IPV) in drug levels, pre-
scription frequency, medication recall) and indirect risk fac-
tors (eg, patient’s mental status, emotional/social status,
adverse effects) of nonadherence. (Level 3)
◯Assess the patient’s social support network and emotional
and mental status (eg, using available questionnaires)
◯ Evaluate the prescription frequency of the proposed
immunosuppressive agent
5. Use different combined methods to objectively identify ad-
herence (eg, questionnaires, drug concentrations) during
the clinical visit. (Level 2)◯ Discuss nonadherence with patients, and on indication, ask
patients to complete a questionnaire
6. Simplified medication regimens, such as fixed-dose, once-
daily medications should be administered to improve adher-
ence. (Level 1)
7. In cases of adverse events, simplify/modify the immuno-
suppressive drug regimen as well as concomitant drugs.
(Level 1)
8. Discuss any suspicion of nonadherence openly and nonjudg-
mentally with the patient. (Level 5)
9. Together with the patient, identify his/her current barriers to
adherence and develop a personalized action plan with spe-
cific solutions, for example, pill boxes, (electronic) reminder
systems, education and psychological behavioral support.
(Level 5)
10. Together with the patient (and team), reassess the results of
the intervention(s) and adjust the strategy when indicated
(eg, residual nonadherence). (Level 5)
11. Patient-level interventions need to focus primarily on behav-
ioral change techniques, including training patients during
inpatient recovery on how to take medications, providing
adherence reminders during clinic visits, etc. Although im-
portant, patient education is only a small component of an
adherence intervention. Informationmust be given in aman-
ner appropriate for the patient. (Level 1)IMPACT OF VARIABILITY OF IMMUNOSUPPRESSIVE
REGIMEN IN LIVERANDKIDNEYTRANSPLANTATION
Problem to be Addressed
In solid organ transplantation, constant and controlled ex-
posure to immunosuppression provides protection against
the development of cellular and antibody-mediated rejection
(AMR) and graft loss, while minimizing drug-related toxic-
ity. Nowadays, the cornerstones of immunosuppression pro-
tocols, both in kidney and liver transplantation, are CNIs,
particularly tacrolimus, which is superior to cyclosporine in
the prevention of T cell–mediated rejection (TCMR) and
graft loss. Oral bioavailability of tacrolimus is poor (25%
mean), and is highly variable among individuals (range,
5-90%).101-103 Tacrolimus is able to be absorbed throughout
the gastrointestinal tract.104 The immediate-release formula-
tion is mainly absorbed in the small bowel. There is extensive
presystemic metabolism by the CYP3A enzymes in the gut
wall and first-pass metabolism in liver, which limits its oral
bioavailability.105 Expressers of the CYP3A5 enzyme (as is more
often the case in black and Asian patients) do require higher dos-
ages to reach therapeutic tacrolimus exposure.105-107 The re-
cently developed prolonged-release formulation in tablet
form (also known as LCP-tacrolimus) is released and ab-
sorbed more distally in the gut.105,106 This newer formula-
tion of prolonged-release tacrolimus in tablets has shown
some differences in terms of pharmacokinetics but long-
term clinical outcome data is yet to be established.106 After
absorption, tacrolimus diffuses extensively in blood cells
and tissues. In the plasma, 90% of tacrolimus is bound to
proteins.103 After being metabolized by the liver, the inactive
metabolites are bile-excreted. Thus, the intrinsic pharmaco-
kinetic and pharmacodynamic properties of tacrolimus,
including erratic absorption, a variable first-pass effect,
and unpredictable metabolism, may be responsible for its
large intrapatient and inter-subject exposure variability.105
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even slight exposure variability can translate into clinically
harmful events.
Clinically significant variability within individual patients
can be defined as an alternation between episodes of overex-
posure and underexposure to immunosuppression within a
timeframe in which the dosage itself remains constant.103
Figure 7 illustrates low IPV and high IPV with similar mean
trough concentrations of CNIs.
In practice, IPVof tacrolimus is usually assessed by the co-
efficient of variance or by standard deviations of trough
concentrations. Persistent significant variability may be re-
sponsible for alloimmune activation during low exposure
and toxicity or low immunity during overexposure. This con-
flicting situation is often seen early after transplantation and
leads to inferior outcomes.103
During pregnancy, the pharmacokinetics properties of
CNIs may vary from the nonpregnant state, so drug levels
should be closely monitored during pregnancy, with dose ad-
justment when necessary.46 Similar considerations may apply
during intercurrent illness.108,109
In renal transplantation, IPV in immunosuppressive drug
exposure is now recognized as a predictor of poor clinical
outcome. In a study of 297 patients, IPV of tacrolimus was
correlated with a composite endpoint comprising graft loss,
biopsy-proven chronic allograft nephropathy and doubling
of plasma creatinine concentration.38 Of 34 patients who
reached the composite endpoint, 24 had increased IPV
(70.6%).38 A larger study (n = 356) confirmed the impact
of IPVon long-term outcome.110 In the largest series to date,
a follow-up of a study performed by Borra et al,38 the impact
of IPV was studied in 808 renal transplant recipients
transplanted between 2000 and 2010.111 Almost a quarter
of the patients (23.3%; n = 188) reached the composite end-
point consisting of graft loss, late biopsy-proven rejection,
transplant glomerulopathy, or doubling of serum creatinine
concentration between month 12 and the last follow-up.
The cumulative incidence of the composite endpoint was
significantly higher in patients with high IPV than in pa-
tients with low IPV (hazard ratio, 1.41; 95% CI, 1.06-1.89;
P = 0.019).111 In addition, increased IPV of tacrolimus has
been associated with the development of de novo DSAs,112
and faster progression of interstitial fibrosis.113
In the context of liver transplantation, the clinical impact
of tacrolimus variability has seldom been studied. Patients
with biopsy-proven TCMR showed increased standard devi-
ations of tacrolimus trough concentrations according to 1FIGURE 7. Concept figure depicting tacrolimus exposure variability. On
narrow range and no significant variability is observed. On the right, pat
periods of overimmunosuppression and underimmunosuppression, thureport.29 In another study, the conversion from twice-daily
tacrolimus to prolonged-release tacrolimus capsules within
the first month after liver transplant resulted in reduced ex-
posure variability, which was accompanied by halved
TCMR rates.114 These studies were hampered by the absence
of multivariate analysis to control for possible confounders.
In addition, the actual hard endpoints in liver transplant,
namely graft loss and death, were not investigated. The most
important study reporting a relationship between tacrolimus
variability and increased likelihood of late rejection and graft
loss was performed in a pediatric population, and it consid-
ered heart, lung, kidney, and liver transplantations together,
making it difficult to draw firm conclusions.115
It may well be that liver transplant recipients are more tol-
erant of tacrolimus variability as compared with renal trans-
plant patients, as they are to TCMR episodes.116 Further
studies with larger sample sizes and longer surveillance pe-
riods are needed to determine to what extent variability in-
creases the risk of graft loss and/or death. In the meantime,
large fluctuations in tacrolimus levels, with high levels of ex-
posure early after liver transplant, should be avoided because
they increase mortality due to overimmunosuppression-
related events, such as infections, cardiovascular events
(CVEs), and malignancies.117
Slightly Modifiable Contributors to
Tacrolimus Variability
Determinants of tacrolimus variability are shown in
Table 4. They are classified according to their detectability
and the ease with which they can be modified by clinicians
and/or patients. Nonmodifiable factors will not be discussed
here because they are hard to detect and/or impossible to
control in daily practice. Slightly modifiable determinants
of variability are easily detected in clinical practice and can-
not be modified per se, but benefit from more frequent as-
sessment of tacrolimus trough concentrations and dose
adjustments. Nonadherence is the paradigm within this cate-
gory (see dedicated section). Gastrointestinal events such as
diarrhea and vomiting may impact on tacrolimus concentra-
tions, and may motivate intensive monitoring until gut func-
tion is restored.118,119
The impact of graft dysfunction on tacrolimus IPV varies
depending on the transplanted organ. In kidney transplan-
tation, the impact is likely to be limited given the intrinsic
pharmacokinetics of tacrolimus (ie, liver metabolism and
bile excretion), although supporting literature is lacking. In
patients needing hemodialysis, it is reasonable to give thethe left, patient A keeps all tacrolimus trough concentrations within a
ient B shows a wide fluctuation of trough concentrations, alternating
s indicating significant exposure variability.
© 2017 Wolters Kluwer Neuberger et al S13next dose immediately after the dialysis session, although no
robust studies are available to support this recommendation.
In liver transplantation, graft dysfunction and/or biliary com-
plications may interfere with metabolism and elimination of
tacrolimus. With mildly impaired liver function, the effect
on tacrolimus pharmacokinetics is negligible.120 However, as
liver function deteriorates, tacrolimus trough concentrations
are expected to rise in an unpredictable and individual man-
ner. Again, close monitoring of tacrolimus levels is required,
and a dosage reduction may be anticipated.
Hypoalbuminemia and anemia may alter the distribution
of tacrolimus by increasing its circulating free fraction, lead-
ing to significant variability and increased exposure.121,122
Therefore, special attention is warranted in patients with
malnourishment and iron deficiency, which are frequent con-
ditions among the transplant population.123
Highly Modifiable Contributors to Variability
Diet content and interactions with other drugs (or some
herbal products) may be the focus of patient education.125,126
Tacrolimus should be taken in a fasting state to increase bio-
availability.127 Foods that interfere with hepatic CYP3A
and/or intestinal CYP3A4 enzymes, such as grapefruit,128,129
pomelo,130 star fruit,131 turmeric, and ginger,132 should be
avoided because they can increase tacrolimus exposure.
Drugs that interfere with CYPmetabolism are able tomodify
tacrolimus exposure when used simultaneously, and some-
times have a clinically significant impact.133 The calcium
channel blocker diltiazem has been used as a tacrolimus-
sparing agent due to its effect as an inhibitor of tacrolimus me-
tabolism.134,135 Evidence in kidney transplant patients suggests
that CYP3A5 expressers are more susceptible to diltiazem-
induced tacrolimus metabolism than nonexpressers.135 The
drugs that are most frequently responsible for interactions with
tacrolimus in the liver transplant population are other immu-
nosuppressants, antifungals, macrolide antimicrobials and
the protease inhibitors commonly used in chronic hepatitis C
virus (HCV) and human immunodeficiency virus (HIV).133TABLE 4.
Determinants of IPV of tacrolimus103,120,121,123,124
Factors
Nonmodifiable • Pharmacogenetics: polymorphisms in CYP3A genes
• Circadian rhythm of tacrolimus exposure
• NonadherenceSlightly modifiable
• Gastrointestinal events (diarrhea, vomiting)
• Any clinical situation motivating liver graft dysfunction
• Low serum proteins (hypoalbuminemia)
• Anemia
Highly modifiable • Food (dietary fat content, grapefruit juice, pomelo)
• Drug–drug interactions: antifungals, antivirals, other
immunosuppressants, and other drugs
• Herbal products
• Uncontrolled generic substitution
Factors are classified according to their detectability and the ease with which they can be modified in rou
CYP3A, cytochrome P450 family 3 subfamily A.Regarding immunosuppressive drugs, anti-IL2 receptor agents
and corticosteroids are able to decrease and increase the tacro-
limus dose requirement, respectively, but the interaction
is usually mild and without clinical consequences.136,137 No
significant interaction is expected when tacrolimus and my-
cophenolate are combined.138 This is in contrast to the re-
duction in mycophenolic acid (MPA) exposure in patients on
co-treatment with cyclosporine. As a result of cyclosporine-
induced inhibition of enterohepatic recirculation, the MPA
area under the curve (MPA-AUC) is significantly lower in case
of cyclosporine as compared with tacrolimus co-treatment.139
The evidence regardingmTORi is contradictory.140,141 Azole an-
tifungals are potent inhibitors of CYP3A4 and P-glycoproteins,
and lead to increased serum concentrations of tacrolimus.
A significant reduction in the tacrolimus dosage should be
anticipated, with recommendations for dose reduction in
the ranges of 40% (fluconazole), itraconazole (50-60% reduc-
tion), 66% (voriconazole), and 75% (posaconazole).142
Furthermore, we recommend reducing the dose at the time
of triazole treatment initiation, and not wait for the first ta-
crolimus concentration after starting a triazole regimen.
Other significant interactions may be experienced when
using other medications sharing CYP3A metabolism (eg,
HIV drugs).143,144
A dedicated comment about hepatitis C antivirals is war-
ranted. With the introduction of new, more potent antivirals,
many transplant patients with HCV may receive therapy af-
ter transplantation. In general, it is mandatory to check for
potential interactions with immunosuppressive drugs in all
transplant patients before starting antiviral therapy. Sofosbuvir,
the cornerstone of most antiviral protocols, and its combina-
tions with ledipasvir or daclatasvir, is usually well tolerated
with tacrolimus.145,146 However, the first-generation prote-
ase inhibitors, telaprevir and boceprevir, and the combina-
tion ombitasvir/paritaprevir/ritonavir+/−dasabuvir, have a
major impact on tacrolimus metabolism, increasing tacroli-
mus trough concentrations exponentially; therefore, these
drugs should be avoided whenever possible.147,148 TheInterventions
Not applicable
(a) More frequent assessment of tacrolimus trough concentrations and
refined dose adjustments
(b) Correction of the underlying factors whenever possible
(c) Additional precaution needed when the patient experiences
liver allograft rejection, infections, liver impairment,
vascular/biliary complications or recurrence of primary liver disease
(d) Specific measures to improve adherence (see dedicated section)
(a) Patient education
(b) Healthy diet. Avoid food contents and herbal products interfering with
hepatic CYP3A and/or intestinal CYP3A4 enzymes
(c) Anticipate and avoid drug interactions
(d) If significant variability occurs, consider switching to
prolonged-release tacrolimus capsules
tine clinical practice.
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age modifications should be carried out according to trough
concentrations.149 Additional and updated information may
be found at www.hep-druginteractions.org.146 HCV infec-
tion also affects tacrolimus and cyclosporine levels, so when
the HCV is cleared, the dose of tacrolimus needs to be re-
viewed and usually increased, to maintain trough levels.150
Another potential source of tacrolimus variability is con-
version to generic formulations; however, the evidence is
scarce and of low quality.151 Bioequivalence between generic
tacrolimus and its innovator has been demonstrated in
healthy volunteers and kidney transplant recipients. In the
subgroup of kidney transplant patients older than 60 years
caution is needed as 1 randomized study showed bioequiva-
lence standards were not met by generic tacrolimus.152 The
evidence for the use of generics in liver transplant population
comes from short and uncontrolled clinical experiences.153
There appears to be insufficient evidence to provide reas-
surance that, in transplanted patients, generics are thera-
peutically equivalent to innovator immunosuppressants.
As outlined in the European Society for Organ Transplanta-
tion (ESOT) recommendations, there are many cases where
prescribing generics is fully appropriate, for example, in
cost-conservative markets.154 Indeed, there are no data to
firmly suggest that generics are not equivalent and therefore
unsafe. However, for narrow therapeutic index drugs, con-
cerns exist regarding the safety of generic substitution given
the clinical consequences linked to both overexposure and
underexposure. Conversion from branded tacrolimus to a
generic formulation should only be undertaken by a trans-
plant specialist and with close monitoring of trough levels.
Uncontrolled switching, particularly between generic formu-
lations, should be avoided.151,154
The conversion from twice-daily to prolonged-release ta-
crolimus (capsules), both in kidney and liver transplant recip-
ients, leads to lower blood trough concentrations and a
reduced IPVof tacrolimus.155,156 In a single study performed
in liver transplant recipients, the early conversion to
prolonged-release tacrolimus capsules was accompanied by
a significant reduction of TCMR rates.114 It remains unclear,
however, whether a reduction in IPVmotivated by conversion
to prolonged-release tacrolimus capsules would also lead to
improved clinical outcomes; prospective trials are needed.157
Finally, in some liver transplant patients experiencing
TCMR or chronic rejection, the transplant physician in-
creases tacrolimus dosage abruptly. This strategy has little
therapeutic impact if the baseline trough concentrations are
within the recommended therapeutic range, but it may lead
to large “intended variability,” particularly when liver func-
tion is impaired.158 If tacrolimus levels are elevated and
graft dysfunction progresses, the risk of high levels of expo-
sure becomes too great, thus increasing mortality due to
overimmunosuppression-related events.117 As a general rec-
ommendation, tacrolimus dosage modifications should be
carried out progressively and with special caution in patients
with liver dysfunction.
Recommendations for Managing IPV in
Kidney Transplantation
1. Regular assessment of the serum trough concentrations of the
immunosuppressivemedication ismandatory (every3months
or when there is an unexplained change in graft function),even in patients who are stable in the long term and are taking
a constant dosage. (Level 1)
2. Potential problems with drug adherence should be
discussed with patients in whom tacrolimus trough con-
centrations fluctuate more than expected, despite a stable
dose. (Level 2)
3. Drug–drug interactions should be anticipated and/or avoided.
(Level 4)
4. In patients with documented variability receiving tacrolimus
twice daily, conversion to once-daily prolonged-release tacro-
limus capsules may be helpful. (Level 4)
5. Substitution to generic tacrolimus formulations, if consid-
ered, should be attempted only in stable patients and under
close monitoring of trough concentrations. Generic substitu-
tion should only be carried out if subsequent substitutions
from one generic to another generic will not be attempted.
(Level 5)
6. Low tacrolimus trough levels will increase the risk of TCMR,
even in the presence of CNI-associated renal impairment.
Therefore, low levels of tacrolimus/underexposure should
be avoided. (Level 5)
Recommendations for Managing IPV in
Liver Transplantation
1. Frequent assessment of CNI serum trough concentrations is
mandatory (every 3 months or when there is an unexplained
change in graft function), even in patients who are stable in
the long term and on a constant dosage. (Level 1)
2. CNI trough levels should be assessed once every 2 or
3 days within the first 15 days after liver transplant, weekly
from week 2 to week 4, monthly until the sixth month after
liver transplant, and every 3 months thereafter. In long-
term stable patients, longer intervals may be acceptable.
(Level 5)
3. Avoiding significant variability, particularly large fluctuations
in tacrolimus trough concentration early after liver trans-
plant, is strongly recommended, as these are associated with
inferior outcomes. (Level 2)
4. Significant variability can be avoided if patients comply with
their pharmacist’s recommendations: this can be optimized
by patient education, healthy diet, and avoidance of use of
drugs and other medicines that affect tacrolimus metabolism.
(Level 4)
5. The occurrence of determinants of variability, such as liver
graft dysfunction, gastrointestinal events, renal impairment
and anemia/hypoalbuminemia should lead to more (eg, at
least weekly) intensive monitoring of tacrolimus trough con-
centrations and dose adjustment if required. Regular surveil-
lance should be resumed as soon as the risk factor for
variability has been corrected. (Level 4)
6. Drug–drug interactions should be anticipated and/or avoided.
Any treatment modification should motivate checking for po-
tential interactions and more frequent assessment of trough
levels. (Level 4)
7. In patients receiving tacrolimus twice daily with documented
significant variability, conversion to once-daily prolonged-
release tacrolimus capsules might be helpful, particularly
early after liver transplant. (Level 2)
8. Substitution to generic tacrolimus formulations should only
be undertaken by a transplant specialist and with close mon-
itoring of trough levels. Uncontrolled switching, particularly
between generic formulations, should be avoided. (Level 5)
9. In patients with histologically confirmed TCMR and baseline
trough concentrations of tacrolimuswithin the recommended
range, an abrupt increase of tacrolimus dosage should be
avoided. (Level 5)
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AND LIVER TRANSPLANTATION
Problem to be Addressed
One of the clinical challenges in managing transplant re-
cipients is to identify and manage those patients who may re-
quire less immunosuppression.159 Strategies for optimal
immunosuppression will vary and transplant units will de-
velop their own regimens, usually based on a CNI—usually
tacrolimus, often with an antimetabolite (such as azathio-
prine) or mycophenolate. Tolerance levels vary not only be-
tween patients, but also over time.159 Some liver transplant
recipients may not require high levels of immunosuppression,
or indeed any immunosuppression in the long term.116 How-
ever, complete withdrawal of immunosuppression is nor-
mally reserved for clinical trials under intense surveillance.159
The clinician needs to strike a balance between over-
immunosuppression, which unnecessarily increases the prob-
ability of developing complications of immunosuppression
such as metabolic, cardiovascular, neoplastic and nephro-
toxic complications, and underimmunosuppression, which
is linked to reduced graft survival and poor patient outcomes
for both kidney and liver transplant recipients.160
The aimof immunosuppressionminimization is to develop
an immunosuppression protocol for the individual recipient,
which provides maximum protection for both patient and
graft from immune-mediated damage with the minimum
immunosuppressive burden. Although the term “immuno-
suppressive burden” is a useful concept, it cannot readily
be measured.
Ten years ago, nephrotoxicity was considered to be a ma-
jor risk factor for kidney graft loss.160 CNI-minimization
strategies for tacrolimus and cyclosporine were proposed
in an attempt to prevent kidney damage and improve pa-
tient outcomes.161 This approach has been challenged,162
and it is now believed that the histological lesions classic-
ally attributed to CNI nephrotoxicity are nonspecific and
some of the allograft damage is a consequence of allo-
immunity.162,163 Thus, it is often difficult to establish
whether renal allograft damage is a consequence of CNI tox-
icity, requiring reduction in CNI dose, or alloimmunity, re-
quiring increased immunosuppression.163
In contrast to kidney transplantation, alloimmunity asso-
ciated with low CNI levels after liver transplantation does
not contribute to damage of the native kidney.163,164 CNI
minimization could, therefore, preserve kidney function in
this instance,165 and reduce other consequences of long-
term immunosuppression. Furthermore, the characteristic
operational tolerance of the liver represents the reduced inci-
dence of rejection episodes and a normal liver function/
histology despite minimal immunosuppression. In fact, the
liver is more forgiving to temporary underimmunosup-
pression after liver transplantation compared with other
solid organs, including the kidney, heart and lung.166 This
immune unresponsiveness has led to some liver transplant re-
cipients being managed on minimal immunosuppressive reg-
imens with CNIs.116 Although tolerance can evolve after
organ transplantation, in most patients, underexposure of
immunosuppression is linked to reduced graft survival and
poor patient outcomes in both kidney and liver transplanta-
tion,117,167 so clinicians must be aware of the factors that
can lead to suboptimal immunosuppression.Patient nonadherence and variability of drug exposure to
immunosuppressive regimens have been discussed elsewhere
within this report; this section focuses on the importance of
physicians managing the risk of underimmunosuppression
in their kidney and liver transplant patients. Because CNI-
based immunosuppression is the most commonly used regi-
men for management of both liver and kidney transplant
recipients, we have focused on CNIminimization in reducing
the immunosuppressive burden. Nevertheless, for some pa-
tients, alternative strategies such asmoving to regimens based
on mTORi, corticosteroids with mycophenolate or azathio-
prine, and regimens based on belatacept (for renal recipients),
may be more appropriate. Some authors have advocated the
use of protocol biopsies to helpmanage immunosuppression.
Absence of evidence of immunological activity may allow for
reduction of the immunosuppressive load; conversely, im-
mune activity, even in the absence of serological abnormali-
ties suggesting graft dysfunction may indicate the need for
increased immunosuppression.168 However, protocol biop-
sies are used relatively infrequently largely because of con-
cerns of safety, cost, and patient acceptance.169
The Basis for CNI-Sparing Regimens
Over the last 10 years, there has been a strong move in the
renal transplant community to minimize CNI-based immu-
nosuppressive regimens, largely based on reports of long-
term nephrotoxicity.161 For liver transplantation, historically,
it was considered that there might be advantages to having
a lower immunosuppressive burden. However, these views
were based on evidence from small patients series, animal
experiments and the immunological role of the liver in
supporting operational tolerance, rather than on data from
RCTs in liver transplantation.170 In 1996, Calne proposed
the window of opportunity for immunological engagement
(WOFIE) hypothesis that some degree of immunological en-
gagement promotes tolerance.171
In 2003, Ojo et al172 reported results of a 5-year study of
69 321 nonrenal transplant patients showing that the cumu-
lative incidence of chronic renal failure was 6.9 to 21.3% (de-
pending on the organ transplanted). In this study, the risk of
chronic renal failure associated with the use of a CNI in-
creased with a cyclosporine regimen compared with tacroli-
mus therapy (overall relative risk 1.24 [1.17-1.30]). In the
same year, Nankivell and colleagues173 reported a 10-year
follow-up study of yearly biopsies in 120 simultaneous kid-
ney and pancreas recipients receiving cyclosporine-based im-
munosuppression and attributed the progressive high-grade
arteriolar hyalinosis with luminal narrowing, increasing
glomerulosclerosis, and additional tubulointerstitial damage
to CNI exposure. Despite the assumed CNI nephrotoxicity
in this study, 10-year death-censored graft survival was
95.2%,with excellent 10-year renal function (mean serum cre-
atinine, 0.14 ± 0.04 mmol/L [1.62 ± 0.48 mg/dL]).173 These,
and other observations, led to the principles that whereas
CNIs reduced acute rejection episodes in the immediate
posttransplant period, in the long term, CNIs were nephro-
toxic, causing fibrotic kidney lesions and leading to poor
long-term graft survival.163
The introduction of mTORi, such as sirolimus, that com-
bine both immunosuppressive and antiproliferative actions
with potentially non-nephrotoxic properties,174 coincided
with the move toward CNI minimization strategies in kidney
aAs per the Advagraf (tacrolimus prolonged-release hard capsules) license recom-
mendations, it is necessary to consider the clinical condition of the patient when in-
terpreting whole blood levels. In clinical practice, whole blood trough levels have
generally been in the range of 5-20 ng/mL in liver transplant recipients and 10-20
ng/mL in kidney transplant patients in the early posttransplant period. During subse-
quent maintenance therapy, blood concentrations have generally been in the range
of 5-15 ng/mL in liver and kidney transplant recipients.
FIGURE 8. DIAMOND study design. *0 to 1000mg IV bolus corticosteroid (preoperatively, intraoperatively, or postoperatively) on day 0. Arm 2
only: if the patient had not received treatment for an acute rejection episode and the last recorded trough level recorded was ≥5 ng/mL at day
43, then the dose was reduced by 20% to 25%. IV, intravenous. Reprinted with permission from Trunecka P, Klempnauer J, Bechstein WO,
et al. Renal function in de novo liver transplant recipients receiving different prolonged-release tacrolimus regimens—the DIAMOND study.
Am J Transplant. 2015;15:1843–1854.178
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avoidance or conversion to mTORi regimens have been in-
vestigated in a number of large, prospective, multicenter, ran-
domized clinical trials in kidney transplantation, with less
study data available for liver transplantation.
Evidence for CNI-Minimization Strategies
In kidney transplantation, studies have failed to show
long-term benefits for transplant recipients on CNI-free regi-
mens.175 These findings are corroborated by the Efficacy
Limiting Toxicity Elimination (ELITE)-Symphony study, a
large, 1-year, multicenter, randomized, controlled study in
1645 kidney transplant recipients.176 Patients were treated
with standard-dose cyclosporine, mycophenolate mofetil
(MMF) and corticosteroids (prednisone or equivalent) versus
daclizumab induction, MMF, and corticosteroids in combina-
tion with low-dose tacrolimus, low-dose cyclosporine, or low-
dose sirolimus.176 Themost favorable outcome for controlling
acute rejection and providing good renal function was ob-
tained in the low-dose tacrolimus arm, with the worst out-
comes in the CNI-free arm.176 At the 3-year follow-up, these
differences had reduced over time and were often not signifi-
cant.177 An overview is provided in Table 5. Additionally, a
large meta-analysis of 56 randomized clinical trials in 11337
renal transplant recipients provides an overview of 3 different
early CNI-sparing strategies161 (Table 5).
Similar to kidney transplantation, CNIminimization strat-
egies using low-dose tacrolimus in liver transplantation have
shown favorable outcomes. Results from a 24-week study of
857 liver transplant recipients (Figure 8) indicated that
lower-dose prolonged-release tacrolimus capsules (0.15-
0.175 mg/kg per day subsequently reduced by 20-25%, target
trough level, 4-12 ng/mL)a, administered with MMF and
basiliximab immediately posttransplant, was associated with
a significant renal function benefit and a significantly lower
incidence of biopsy-confirmed acute rejection, compared with
a higher-dose (5-15 ng/mL until day 42 then 5-12 ng/mL)
prolonged-release tacrolimus-based regimen.178
The Impact of Underimmunosuppression
In kidney transplantation, excessive minimization of im-
munosuppression can lead to the development of DSAs andpossible TCMR, with a negative impact on kidney graft sur-
vival.179 Using Luminex assays, Liefeldt et al179 prospectively
assessed the presence of DSAs in 126 patients who had either
received cyclosporine-based immunosuppression or had been
randomized to everolimus and MMF conversion at 3 to
4.5 months, with progressive withdrawal of steroids in
60%of patients. DSAs developed in 10.8%of patients on cy-
closporine and 23.0%of patients on everolimus; significantly
more patients developed TCMRwith everolimus (n = 8) ver-
sus cyclosporine (n = 2; P = 0.036).179 The appearance of
DSAs could be considered a biomarker of underimmuno-
suppression after kidney transplantation, although these an-
tibodies may become detectable only after the initiation of
organ damage.179,180
There is increasing evidence that the formation of de novo
DSAs in liver transplantation is an independent risk factor for
graft loss.39,181 Underimmunosuppression immediately after
liver transplantation carries a higher risk of rejection.158 Ta-
crolimus trough concentrations less than 7 ng/mL in the first
week after liver transplantation is associated with higher
rates of moderate/severe rejection compared with levels
greater than 7 ng/mL.117 In the first year after liver transplant,
underimmunosuppression (tacrolimus levels <3 ng/mLa or cy-
closporine levels <75 ng/mL) is associated with an increase in
de novo DSA formation.39 However, in liver allografts (and
in contrast to kidney transplants), early acute cellular rejection
does not appear to be associated with worse graft outcomes.
Optimizing Immunosuppression Levels
The Collaborative Transplant Study (CTS) report in 2014
found that kidney transplant recipients are at a significantly
higher risk of graft failure due to alloimmunity if maintained
on tacrolimus trough levels less than 5 ng/mL at year 1
posttransplant compared with patients maintained at
TABLE 5.
Results of studies investigating CNI-free/minimization regimens161,176-178
Study type No. of participants Intervention Results
ELITE-Symphony study (large, 1-year,
multicenter, randomized, controlled
study). The study was then
extended to 3 years
1645 renal transplant
recipients
Patients were treated with either:
– MMF and corticosteroids (prednisone or
equivalent), standard-dose cyclosporine
Or
– MMF, corticosteroids (prednisone or
equivalent), and daclizumab induction,
with low-dose cyclosporine, low-dose
tacrolimus, or low-dose sirolimus
– The most favorable outcome for controlling
acute rejection and providing good renal function
was obtained in the low-dose tacrolimus arm,
with the worst outcomes in the CNI-free arma
– At the 3-year follow-up, these differences had
reduced over time and were often not significant,
but many patients were switched from sirolimus
and cyclosporine to tacrolimus
Large meta-analysis of
56 randomized clinical trials
11 337 renal transplant
recipients
– Patients were treated with three
different early CNI-sparing strategies:
CNI avoidance, CNI minimization and the
delayed introduction of CNIs
– The use of mTORi, in combination with MMF
and no CNIs, increased the odds of graft failure
(OR, 1.43; 95% CI, 1.08-1.90; P = 0.01)
– CNI-sparing strategies were associated with
fewer cases of DGF (OR, 0.89; 95% CI,
0.80-0.98; P = 0.02), improved graft function,
and fewer cases of new-onset diabetes
DIAMOND study (multicenter,
24-week, randomized study)
857 liver transplant
recipients
Patients were treated with:
– Prolonged-release tacrolimus (initial dose
0.2 mg/kg/day) + MMF
Or
– Prolonged-release tacrolimus
(0.15-0.175 mg/kg/day) + basiliximab + MMF
Or
Prolonged-release tacrolimus (0.2 mg/kg/day
delayed until Day 5) + basiliximab + MMF
Lower-dose prolonged-release tacrolimus capsules
(initially 5-15 ng/mL, then 4-12 ng/mL after 3 months)b,
administered with MMF and basiliximab immediately
posttransplant, was associated with a significant renal
function benefit and a significantly lower incidence
of BCAR, compared with a higher-dose (5-15 ng/mL
until day 42 then 5-12 ng/mL) prolonged-release
tacrolimus-based regimen
a The actual levels in the low-dose arm were at the top of the target range (approximately 7 ng/mL, rather than 3-7 ng/mL).
b As per the Advagraf (tacrolimus prolonged-release hard capsules) license recommendations, it is necessary to consider the clinical condition of the patient when interpreting whole blood levels. In clinical practice,
whole blood trough levels have generally been in the range of 5-20 ng/mL in liver transplant recipients and 10-20 ng/mL in kidney transplant patients in the early posttransplant period. During subsequent main-
tenance therapy, blood concentrations have generally been in the range of 5-15 ng/mL in liver and kidney transplant recipients.
BCAR, biopsy-confirmed acute rejection; ELITE, Efficacy Limiting Toxicity Elimination.
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7-9.9 ng/mL, ≥10 ng/mL; P < 0.001). Long-term data from
the CTS also showed that maintaining tacrolimus trough
levels at ≥5 ng/mL versus <5 ng/mLb had a beneficial effect
on renal function over 5 years of treatment.36 The Symphony
study confirmed that patients with a mean tacrolimus
trough level of 6.4 ng/mL at year 1 and 6.5 ng/mL at year
3 had better allograft survival compared with patients in
the standard-dose cyclosporine, or low-dose sirolimus
treatment groups.177
In liver transplantation, current clinical opinion suggests
optimal target trough levels are 6 to 10 ng/mL in the first
month posttransplant, decreasing to 4 to 8 ng/mLb (except
in combination with mTORi) after the first month. This con-
sensus is backed up by a systematic review andmeta-analysis
of 64 studies (32 randomized controlled, 32 observational),
published in 2013, which found that tacrolimus trough con-
centrations of 6 to 10 ng/mL in the first month posttransplant
led to a twofold reduction in renal impairment, with no in-
crease in TCMR.158 A further study investigating tacrolimusbAs per the Advagraf (tacrolimus prolonged-release hard capsules) license recom-
mendations, it is necessary to consider the clinical condition of the patient when in-
terpreting whole blood levels. In clinical practice, whole blood trough levels have
generally been in the range of 5-20 ng/mL in liver transplant recipients and 10-20
ng/mL in kidney transplant patients in the early posttransplant period. During subse-
quent maintenance therapy, blood concentrations have generally been in the range
of 5-15 ng/mL in liver and kidney transplant recipientsexposure within the first 15 days after liver transplantation
found that patients with trough levels greater than 7 ng/mL
experienced less moderate/severe rejection compared with
patients with trough levels less than 7 ng/mL over an approx-
imate 7-year follow-up.117 Although lower tacrolimus
trough levels are still sometimes used as a target within real-
world clinical practice,158 this is in contrast to some clinical
guidelines, regulatory authority and pharmaceutical industry
recommendations which only support target tacrolimus
trough concentrations of greater than 10 ng/mL in the first
6 weeks after liver transplantation.117
Factors suggesting an increased need for immunosuppres-
sion include original indication for transplant (autoimmune
liver diseases such as autoimmune hepatitis, primary scleros-
ing cholangitis (PSC), or primary biliary cholangitis) and
retransplant for rejection.182,183
The level of immunosuppression required is usually
greater than for those grafted for hepatocellular carcinoma
(HCC), alcohol or hepatitis B virus (HBV)-related liver dis-
ease.184 For those grafted forHCV,where there is ongoing vi-
ral replication, higher levels of immunosuppression are
related to increased viral replication, so the clinician must
balance the need to prevent rejection (as high-dose antirejec-
tion immunosuppression will greatly enhance viral replica-
tion and graft damage) and the need to maintain a low
burden of immunosuppression.184,185 Other factors that are
associated with a greater need for immunosuppression in-
clude those with greater variation in drug levels. Optimal
S18 Transplantation ■ April 2017 ■ Volume 101 ■ Number 4 www.transplantjournal.comtarget trough levels for those liver allograft recipients on com-
bination therapy remain unclear.
Despite the lack of data on immunosuppression-
minimization strategies in liver transplantation, complete
immunosuppression withdrawal has shown to be feasible
in approximately 20% of carefully selected liver transplant
recipients.159 These patients are generally older, with a lon-
ger time posttransplant,159 not transplanted for autoim-
mune diseases and with no evidence of rejection at the
time of immunosuppression withdrawal.
In a retrospective study of 78 patients (mean age, 53 years),
with a median time from liver transplant to drug conversion
of 12 months, switching from a CNI-based immunosup-
pression regimen to a CNI-free mTORi regimen (everolimus
or sirolimus) improved renal function. The rejection rate
(5.1%) was similar compared to patients maintained on the
CNI-based regimens.186 However, to fully elucidate long-
term outcomes of these strategies, large clinical trials on
CNI minimization and withdrawal are needed.159,187
In a prospective multicenter study, of 500 screened liver
transplant recipients, 102 were enrolled into a withdrawal
trial. Of these, 41were found tolerant, 57 developed acute re-
jection 6.44 months after the start of drug minimization
(standard deviation, 4.37; range, 1.28-21.35). On liver bi-
opsy 1 year after weaning of immunosuppression, portal in-
flammation, interface hepatitis and lymphocytic cholangitis
were found more frequently. These changes, however, were
mild and could no longer be observed 3 years after drug dis-
continuation. Macrovesicular steatosis was also found with
further progression (up to 20%; P < 0.001) over time. De-
spite many limitations, this very interesting study has
showed that weaning of immunosuppression could be feasi-
ble in a minority of carefully selected patients long term
after transplantation.164
Strategies for Prevention of Underimmunosuppression
In kidney transplantation, it is important to stratify pa-
tients according to their immunological risk.
Higher risk patients include those who188:
• Are sensitized from previous blood transfusions or
previous transplant
• Had successive pregnancies
• Present with HLA-DR mismatch
• Panel reactive antibody (PRA) above 0%, and preformedDSAs
• Younger age at time of transplant
• Recipients of black ethnicity
A standardCNI protocol is generally advisable in these pa-
tients,188 with target trough levels of tacrolimus between 5
and 10 ng/mL and concomitant use of azathioprine, myco-
phenolate or corticosteroids.
In liver transplantation, although it is easier to reverse the
effect of underimmunosuppression compared with the ad-
verse effects of overimmunosuppression, defining and adher-
ing to the appropriate target levels for immunosuppressive
regimens should remain a priority.
There is also a strong unmet need for pharmacodyna-
mic biomarkers that reflect the biological effect of the immu-
nosuppressive regimen to guide dosing in individual patients.
An immune function assay, investigated in a liver transplant
RCT, has shown additional benefits for optimizing immuno-
suppression and improving patient outcomes.189It is important to take into account that the “how low can
you go” immunosuppression considerations of the past
10 years,160 have now shifted toward the need to maintain
immunosuppression at a certain minimum level.
Recommendations for Managing
Underimmunosuppression in Kidney Transplantation
1. Determine pretransplant risk factors and immunological risk
status for each patient before transplantation. (Level 1)Pretransplant risk factors, including patients with
a “higher risk” immunological risk status188
• Sensitized from previous blood transfusion(s), previous
transplant, or pregnancies
• HLA mismatch (particularly HLA-DR mismatch)
• PRA >0% (HLA antibodies)
• Preformed HLA-DSA
• Younger age at time of transplant
• Adolescents are at higher risk of nonadherence
• Black recipient ethnicity
• Previous graft loss as a result of immunological reasons2. Take into account both the risks and the benefits to each
individual patient when determining their immunosup-
pressive regimen and optimal trough levels. Consider the
following: (Level 2 or Level 3)
◯ Aim for tacrolimus target trough levels of 5 to 10 ng/mL in
the first year after transplantation (Level 1)
3. Identify patients potentially at higher risk of underimmuno-
suppression, including young patients, adolescents and pa-
tients who have previously lost a graft due to immunological
causes. (Level 1)
◯ For higher risk patients, consider induction therapy (Level 1)
◯ The standard CNI protocol is generally advisable in higher
risk patients with trough target levels of tacrolimus between
5 and 10 ng/mL and concomitant use of azathioprine, my-
cophenolate or corticosteroids (Level 5)
◯Monitor nonadherence and the development of adverse
events (for recommendations on nonadherence, please
see the relevant chapter)
4. Discourageminimization of immunosuppression unless there is
a convincing reason (eg, polyomavirus-associated nephropa-
thy), due to the increased risk of TCMR and AMR. Any mini-
mization strategies involving CNI reduction, avoidance or late
conversion should be carefully evaluated in each patient and
the risks and benefits weighed. (Level 1)Recommendations for Managing
Underimmunosuppression in Liver Transplantation
1. Take into account both the risks and the benefits to each indi-
vidual patient when determining their immunosuppressive
regimen and optimal trough levels. Consider the following:
original liver disease, overall status (age, nutritional status, tu-
mor history, infection status, etc.) and transplant history
(other organ transplantation, causes of graft loss). (Level 3)
© 2017 Wolters Kluwer Neuberger et al S192. After transplantation, avoid underimmunosuppression (tacro-
limus trough levels <6 ng/mL in the absence of induction
agents, other immunosuppressive agents or mTORi). (Level 1)
3. a) Aim for tacrolimus target trough levels of 6 to 10ng/mL in the
first month after transplantation, reduced to 4 to 8 ng/mLc
in the maintenance phase after the first month (Level 1)
b) For combination therapy, lower tacrolimus trough levels
(4-12 ng/mL)c are acceptable with MMF, mTORi, and
basiliximab induction therapy (Level 2)
c) For combination therapy where tolerability/toxicity is an is-
sue, lower tacrolimus trough levels are acceptable. (Level 4)4. Maintenance steroids are generally unnecessary for the avoid-
ance of TCMR in liver transplantation. Inmost scenarios, ste-
roids can be safely withdrawn within the first 6 months after
liver transplant. (Level 1)
5. Withdrawal of immunosuppression after liver transplantation
should be confined to a research environment under strict clin-
ical and histopathological surveillance protocols. (Level 3)ADVERSE EFFECTS RELATED TO
IMMUNOSUPPRESSION IN KIDNEYAND
LIVER TRANSPLANTATION
Problem to be Addressed
Kidney transplant recipients and the vast majority of liver
transplant recipients require lifelong immunosuppression
to maintain graft integrity. However, immunosuppressive
agents inhibit the immune system beyond the alloimmune
response, particularly when immunosuppression levels are
high. This results in adverse effects, including generic effects
(eg, increased risk of infections and certain cancers), class ef-
fects (eg, renal impairment with CNIs), and drug-specific
side effects.190,191 The clinical impact of toxicities associ-
ated with immunosuppression has led to the concept of min-
imization of immunosuppression and combination of drugs
in low concentration.192 This is discussed further in the
underimmunosuppression section.
In the absence of early biomarkers of overimmuno-
suppression, HCPs are therefore faced with maintaining the
delicate balance of suppressing the immune response to pre-
vent graft rejection, and avoiding unnecessarily high levels
of immunosuppression.193,194 Therapeutic drug monitoring
of trough levels is performed; however, trough levels only
provide an indirect measure of immunosuppression. Over-
immunosuppression is often late to be identified, generally
after the diagnosis of related adverse effects.192 Although
the reduction of immunosuppression is common practice in
patients with infection or neoplasm, there are no clear guide-
lines on howmodification of the immunosuppressive regimen
should be managed for the different types of adverse events.
Risk stratification, preventative measures and early detection
of adverse events in liver and kidney transplant recipients are
therefore paramount for graft and patient survival.
Immunosuppression can lead to poorer patient and graft
survival by increasing the risk of fungal, bacterial, or viral
infections (eg, Epstein–Barr virus [EBV], cytomegalovirus
[CMV], polyomavirus, human herpes virus), developmentcAs per the Advagraf (tacrolimus prolonged-release hard capsules) license recom-
mendations, it is necessary to consider the clinical condition of the patient when in-
terpreting whole blood levels. In clinical practice, whole blood trough levels have
generally been in the range of 5-20 ng/mL in liver transplant recipients and 10-20
ng/mL in kidney transplant patients in the early posttransplant period. During subse-
quent maintenance therapy, blood concentrations have generally been in the range
of 5-15 ng/mL in liver and kidney transplant recipients.of certain malignancies, renal insufficiency, cardiovascular
risk and metabolic complication.193-195 Infections occur more
commonly during the first year of transplant, when immuno-
suppression levels are highest (Figure 9).193,195
On the other hand, malignancies (other than post-
transplant lymphoproliferative disease [PTLD]) tend to occur
after the first year of transplantation, presumably due to cu-
mulative immunosuppression.193 The 2010 study by Collett
et al196 compared the incidence of malignancy in solid organ
transplant recipients with the general population in the
United Kingdom, using standardized incidence ratios matched
for age, sex, and time period. The study showed the 10-year
incidence of de novo cancer in transplant recipients is twice
that of the general population, with the incidence of non-
melanoma skin cancer being 13 times greater.196 Risk factors
for malignancies vary for different tumor types, with the de-
velopment of some cancers being linked to viral infections.193
In liver transplant recipients, de novo neoplasms are one of
the most common causes of late mortality.197
Certain biomarkers associated with risk of infection, such
as low levels of IgG,198 complement C3 fraction,199 mannose-
binding lectin levels,200 or low CD4- and CD8-positive T-cell
counts,201 may eventually provide a role in helping to predict
infection in liver and kidney transplant recipients.198,202 Two
assays have been developed in this field. The Cylex
ImmuKnow Cell Function Assay measures T-cell function
by the release of adenosine triphosphate from CD4-positive
lymphocytes in culture after a mitogenic stimulus.203 The
T-cell IFN-γ enzyme-linked immunospot (ELISPOT) assay
quantifies memory T-cells in peripheral blood that respond
to donor HLAs or CMV antigens.204 The clinical utility of
both these biomarker assays in clinical practice is yet to
be determined.
Kidney Transplantation
Overimmunosuppression and Infection
Increased risk and severity of infection are explained by
many factors, including the recipient’s condition, such as sur-
gical complications, or the use of indwelling catheters; the
possibility of transmission of infection from donor to recipi-
ent; overimmunosuppression; active smoking; and obesity,
etc.205 Viral infections, which occur more frequently during
the first few months after transplantation, are most likely in
the context of greater immunosuppression.195,204,206-208
Furthermore, recipient age is often a significant risk factor
for bacterial infections, but not viral/fungal infections.209
Type of immunosuppressive agent such as use of induction
therapy with antithymocyte globulin is also associated with
viral infections.195Common viral infections in kidney transplantation
Cytomegalovirus
Polyomavirus
Epstein–Barr virus
Human herpes virus (HHV-6, HHV-8)
Varicella-zoster virusPolyomavirus-associated nephropathy (PVAN) is probably
the most specific infectious complication after kidney trans-
plantation, indicating clinical overimmunosuppression.204,210
FIGURE 9. Infections in solid organ transplant recipients. The timeline of infections after organ transplantation. The risk for infection after organ
transplantation follows a standard pattern with routine immunosuppression and infectious exposures. The potential pathogens for which the
risk is modified by prophylaxis, including vaccinations and antimicrobial agents, are indicated (*). Individual risk is modified by events such as
surgery, treatment of graft rejection, or malignancy. Note that graft rejection and drug reactions may be among noninfectious causes of fever
in transplant recipients. JC virus, John Cunningham virus; HSV, herpes simplex virus. Modified with permission from the author; reprinted with per-
mission from Fishman JA. Opportunistic infections – coming to the limits of immunosuppression? Cold Spring Harb Perspect Med. 2013;3:1–14;
original source of data: Fishman J. Infection in solid-organ transplant recipients.N Engl J Med. 2007;357:2601–2614. Adaptations are themselves
works protected by copyright. So in order to publish this adaptation, authorization must be obtained both from the owner of the copyright in the
original work and from the owner of copyright in the translation or adaptation.195,205
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transplant recipients for human BK polyomavirus, the major
cause of PVAN, which puts 1% to 15% of kidney transplant
patients at risk of premature allograft failure.211
The relationship between bacterial infection and overimmu-
nosuppression is well established. However, in many cases
there are additional identifiable risk factors for bacterial infec-
tion, including surgical complications, intravenous or urinary
catheters, urinary retention or vesicoureteral reflux.195,205,212
Patients with a tuberculin purified protein derivative-positiveskin test or a positive IFN-γ release assay for tuberculosis
(TB) before transplantation are also at increased risk ofMyco-
bacterium tuberculosis infection after transplantation.213,214
Prophylaxis is an efficient strategy to prevent some com-
mon posttransplant infections, such as TB, CMV and the
fungal infection Pneumocystis jirovecii, more closely asso-
ciated with high steroid exposure.195 Ganciclovir or
valganciclovir prophylaxis can prevent CMV infections. Pro-
phylaxis of CMV infection also prevents secondary events
such as acute allograft rejection or other opportunistic
FIGURE 10. Screening and management of kidney transplant recipients for BKV replication and PVAN. BKV, BK virus; EM, electron micros-
copy; IVIG, intravenous immunoglobulin. Reprinted with permission from Hirsch HH, Randhawa P. BK polyomavirus in solid organ transplan-
tation. Am J Transplant. 2013;13(Supp. 4):179–188.211
© 2017 Wolters Kluwer Neuberger et al S21infections. Trimethoprim-sulfamethoxazole, administered to
prevent Pneumocystis jirovecii, also decreases the rate of uri-
nary infections after transplantation.195,205
In patients with subclinical or clinical infections, especially
viral infections, reduction of immunosuppression favors an
immune response against microorganisms.205 Treatment with
mTORi is associated with a reduced incidence of posttrans-
plantCMVinfection.215Although, this effect has led to sugges-
tions that CMV prophylaxis may not be necessary, this needs
to be explored further.216-218 Similarly, some reports suggest
that mTORi regimens have a lower incidence of PVAN.219
Overimmunosuppression and Cancer
The risk of cancer is increased after kidney transplantation;
the relationship between cancer incidence and immunosuppres-
sion depends on the type of cancer, the immunosuppressive bur-
den, and time posttransplant. The Standardized IncidenceRatios
(SIR) for the most commonmalignancies in kidney transplant
recipients include: Kaposi’s carcinoma (17.1), nonmelanoma
skin cancer (16.6), and cancer of the lip (65.6).196
Certain immune characteristics in the recipient, such as an
increased number and proportion of regulatory T-cells, may
prove to be useful in stratifying cancer development after
transplantation.220 Prevention and screening for cancer, suchas gynecological and breast cancer, and prostate cancer,
should follow the same recommendations as for the general
population.221 Studies have shown that the clinical benefit
of colorectal cancer screening in patients with functioning
kidney transplants may well be equivalent to the benefit
found in the general population.222
Decreasing immunosuppression is common practice in kid-
ney transplant patients with cancer; however, this is associated
with an increased risk of graft rejection.223 AnmTORi with an-
tineoplastic properties can be used for reducing the occurrence
of new cancers and preventing cancer recurrence in allograft
recipients who received allografts for renal cell carcinoma,174
and is effective in Kaposi’s sarcoma224 and nonmelanoma skin
cancer.225 In kidney transplant recipients, further trials of
mTORi are ongoing in secondary prevention of nonmelanoma
skin cancer226,227; there is evidence in these patients for
mTORi in the reduction of de novo cancer incidence.228
Liver Transplantation
Overimmunosuppression and Infection
Invasive fungal infection is associated with high morbidity
and mortality in liver transplant recipients,229,230 with can-
didiasis, aspergillosis and cryptococcosis respectively being
the most common fungal infections.229 It is important to
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care unit (ICU) pretransplant, for fungal colonization, to de-
termine whether targeted pretransplant or posttransplant
antifungal prophylaxis is required.230 The improvement of
perioperative and postoperative care, modification of im-
munosuppression, use of prophylactic measures such as
trimethoprim-sulfamethoxazole against pneumocystic pneu-
monia, and fluconazole in high-risk patients waiting for a
liver graft in the ICU, have led to a reduction in invasive fun-
gal infections postliver transplant.205,230
CMV infection is also common postliver transplant.231
Prophylaxis with valganciclovir in high-risk patients (CMV-
seropositive donors in CMV-seronegative recipients) im-
proves outcomes.232 It has also been suggested that mTORi
may decrease the incidence of CMV infections; however,
more studies are required.233
Recurrence of HBV infection is almost universal after liver
transplantation without hepatitis B immunoglobulin (HBIg)
prophylaxis. All HBV-positive patients undergoing transplan-
tation for HBV-related end-stage liver disease and active viral
replication should be treated before transplantation with a po-
tent nucleos(t)ide analog that has a high barrier to resistance.234
Nucleos(t)ide analogs in combination with HBIg have shown a
reduction in the risk of graft infection to less than 10%.234,235
Also, entecavir prophylaxis withoutHBIg is proven to be clin-
ically well tolerated and an effective option for the prevention
of HBV recurrence.236 Monitoring of renal function should
be regularly performed if nucleos(t)ide analogs are used.
Liver disease attributed to chronicHCVinfection is a com-
mon indication for liver transplantation in Europe.237 Recur-
rence of chronic HCV infection postliver transplantation is
universal in recipients with detectable HCV RNA and it is a
risk for graft loss and poor patient survival due to rapid pro-
gression to cirrhosis or fibrosing cholestatic hepatitis.237,238
Prophylaxis with direct-acting antiviral agents has revolu-
tionized HCV recurrence therapy in liver transplant recipi-
ents, showing high sustained virological response rates,
shorter treatment duration and reduced adverse events com-
pared with interferon- and ribavirin-based therapies.237 In
general, it is mandatory to check for potential interactions
with immunosuppressive drugs in all transplant patients be-
fore starting antiviral therapy.
Overimmunosuppression and Cancer
De novo neoplasms are one of the most common causes of
late mortality in liver transplant patients (cumulative incidence
of 34.7% at over 15 years postliver transplant versus 8.9% in
the nontransplanted population), and typically associated
with male sex and patients aged >34 years.197 The most com-
mon malignancies directly related to immunosuppression are
nonmelanoma skin cancers and PTLD (Table 6).239TABLE 6.
Risk factors associated with common malignancies postliver tra
Cancer type
Nonmelanoma skin cancers Age >40 y
PTLD
Head and neck or lung cancers
Colorectal carcinomas
Table based on data from Chak and Saab, 2010.239Patientswith a history of alcohol abuse and smoking have a
high risk of upper gastrointestinal, oropharyngeal-laryngeal
and lung cancers.239 Patients transplanted for PSC and in-
flammatory bowel disease (IBD) are at an increased risk for
colorectal carcinoma.239
HCC is a leading indication for liver transplantation.240
With the improved selection criteria and preoperative bridg-
ing therapies available, the HCC recurrence rate at 5 years
postliver transplant, which is fatal in the majority of patients
within 1 year after diagnosis, is now at an acceptable level
(<20%).240 Challenges still remain, however, in determin-
ing the type and dose of immunosuppressive therapy
posttransplant to further reduce HCC recurrence and im-
prove its prognosis. CNIs in general are reported as having
direct prooncogenic activity241; high levels of cyclosporine
(>300 ng/mL) and tacrolimus (>10 ng/mL) have been associ-
ated with an increased risk of HCC recurrence.242
mTORi have antiangiogenic and antiproliferative proper-
ties.243 One recent randomized, phase 3 open-label study has
shown that sirolimus in liver transplant recipients with HCC
does not improve long-term (5-year) recurrence-free survival,
but there may be some benefit in the first 3 to 5 years, espe-
cially in low-risk patients.244 Although some studies suggest
that T-cell antibody induction may have a negative effect in
terms of neoplasm development, a systematic review found
no differences in the development of malignancies or HCC re-
currence versus placebo.245 As such, chronic maintenance im-
munosuppressionmight play amore important role than short
intense periods of immunosuppression.
Managing cancer risk posttransplant remains challenging.
Despite the increased risk of malignancies, tumor screening
programs are not validated in the liver transplant setting.221
Findings from the National Lung Screening Trial Research
Team highlight that screening high-risk individuals with
low-dose computed tomography reducesmortality from lung
cancer in the general population246; thismay prove to be ben-
eficial in high-risk liver transplant recipients (with a history
of, or still smoking).
In liver transplantation, accepted tumor surveillance op-
tions include yearly colonoscopies in patients with PSC and
IBD, as well as annual skin examinations in all patients.239,247
Renal Impairment
There is some evidence that a link exists between the use of
CNIs and renal impairment postliver transplant.248,249 How-
ever, CNIs remain necessary to prevent rejection ≤1 year
postliver transplant.37 A long-term beneficial effect on renal
function can be achieved by combining reduced-dose CNIs
with non-nephrotoxic immunosuppressive agents early after
liver transplantation.248,250 Interventions later on are less
successful,114 therefore, a preferable approach is earlynsplantation
Risk factors
ears, male sex, skin type, sun exposure, smoking and previous alcohol abuse
Age >50 years and EBV infection
History of alcohol abuse and smoking
PSC and IBD
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with MPA or everolimus.248,250,251 In the case of everolimus,
this results in a significantly better renal function at 2 years af-
ter transplantation.250 Started after 1 year postliver transplant,
MMF combined with CNI reduction still can improve renal
function.251 The randomized controlled DIAMOND study
(Figure 8) showed that an initial lower dose prolonged-
release tacrolimus capsules regimen, or the delayed initiation
(Day 5) of the higher dose prolonged-release tacrolimus cap-
sules regimen (together with MMF and basiliximab), was as-
sociated with significant improvement in renal function at
6 months, compared to the prolonged-release tacrolimus-
based regimen administered at a higher initial dose immedi-
ately after transplantation.178 A recent nonrandomized study
showed that conversion from immediate-release to prolonged-
release tacrolimus >1 month postliver transplantation limits
the increase in serum creatinine concentrations.114
It is generally accepted that methods based on serum creat-
inine for the detection of kidney dysfunction underestimate
the extent of renal impairment in transplant recipients. As
such, limited effective interventions are available by the time
an elevation in serum creatinine levels is detected. There is,
therefore, a need for timely intervention and early and sensi-
tive indicators to detect CNI-related nephrotoxicity. Cystatin
C-based calculations have been shown to be superior in esti-
mating glomerular filtration rate (GFR) compared with
creatinine-based estimations; however, GFR is still underes-
timated using this method in patients with low GFR.252Strategies to reduce the risk of renal impairment
postliver transplantation
1. Induction therapy with reduced or delayed initiation of
prolonged-release tacrolimus capsules combined with
MMF and basiliximab
2. Early after liver transplantation combination of low-dose
CNI with MMF or everolimusMetabolic Syndrome
Metabolic syndrome is highly prevalent after liver trans-
plantation, with an incidence of 50% to 60% in liver trans-
plant recipients. Therefore, liver transplant recipients are at
a high risk of cardiovascular complications—ranging from
approximately 10% at 5 years to up to 25% at 10 years.238
As a priority, all elements of metabolic syndrome should be
treated, including arterial hypertension, hyperlipidemia, dia-
betes mellitus and obesity.
Conversion from CNIs to mTORi increases the incidence
of diabetes mellitus and arterial hypertension postliver trans-
plant.253,254Moreover, compared with CNIs, mTORi are as-
sociated with a higher incidence of dyslipidemia.174 On the
other hand, the results from several studies suggest a reduced
weight gain with mTORi versus CNIs.255
Recommendations for theManagement andPrevention
of Adverse Effects Related to Immunosuppression in
Kidney Transplantation
1. Patients with a positive purified protein derivative skin test
or a positive IFN-γ release assay for TB should receive pro-
phylaxis (isoniazid for 9 months). (Level 3)◯Advocate TB prophylaxis in patients of Indian subcontinent
origin (Level 5)
2. Prophylaxis (trimethoprim-sulfamethoxazole) should be
given to all patients during the first 6 months after kidney
transplantation to prevent Pneumocystis jirovecii infection,
and in patients treated with mTORi, the duration of pro-
phylaxis could be extended. (Level 1)
3. Prophylaxis for CMV infection with valganciclovir should
be given for 6 months in recipient-negative/donor-positive
(R-/D+) renal transplant patients, for 3 months in D+ pa-
tients, or as a preemptive strategy based on nucleic acid am-
plification testing. (Level 1)
4. BK viremia should be regularly monitored (at least every
3 months) during the first 24 months. (Level 2)
5. In patients with consistent BK viremia (presenting 2 consec-
utive positive determinations), consider step-wise reduction
of immunosuppression and renal biopsy. (Level 3)
6. In patients with persistent BK viremia and increasing pro-
teinuria and/or deterioration of renal function, a renal bi-
opsy is indicated to confirm pathology. (Level 3)
7. Prevention and screening for cancer should follow the same
recommendations as for the general population (eg, gyneco-
logical, breast, prostate or colon cancer screening). (Level 5)
8. Self-examination by patient and annual dermatological exam-
ination (by the primary care physician or dermatologist) are
recommended for the early detection of skin cancer. (Level 3)
9. Yearly abdominal ultrasound examination is recommended
for the detection of intra-abdominal tumors, especially can-
cer of the native kidneys. (Level 5)
10. Patients:
◯ With Kaposi’s sarcoma should be switched to an mTORi
when possible (Level 1)
◯ With nonmelanoma skin cancer, the use of mTORi should
be considered in the individual patient by weighing up the
risks and benefits (Level 2)
11. Immunosuppression reduction in patients with cancer
should be balanced, taking into consideration the prognosis
of cancer, the type of antineoplastic therapy and the risk of
rejection. (Level 4)
Recommendations for theManagement andPrevention
of Adverse Effects Related to Immunosuppression in
Liver Transplantation
1. Liver transplant recipients surviving post-1 year after trans-
plantation should be monitored every 3 months for the first
5 years then at least every 6 months, or when complications
develop for evidence of unwanted side effects of immunosup-
pression, such as:
◯ Renal impairment (Level 1)
◯ Development of skin cancer and PTLD (Level 1)
◯New onset of diabetes, obesity, arterial hypertension and hy-
perlipidemia (Level 1)
2. Liver transplant recipients should be screened annually for
malignancies:
◯Annual dermatological screening (by the patient and the pri-
mary care physician or dermatologist) regardless of age
(Level 3)
◯Annual colonoscopies should be performed in patients receiv-
ing liver transplants for PSC who also have IBD (Level 3)
◯ Liver transplant patients should be encouraged to adhere to
established population screening programs for common
malignancies in the general population (Level 3)
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dent on the patient’s situation:
◯ mTORi-based immunosuppression can be used for second-
ary prevention of squamous cell carcinoma of the skin or
treatment of Kaposi’s sarcoma based on the kidney trans-
plant experience (Level 4)
◯ CNI-based immunosuppression is preferred over mTORi in
patients at risk of developing dyslipidemia (Level 2)
◯ Decline of renal function postliver transplant can be re-
duced by:
▪ Using a combination of reduced-dose CNIs with mTORi
or mycophenolate (Level 1)
▪ Conversion from immediate-release to prolonged-release
tacrolimus capsules (Level 3)4. Routine screening and vaccination should be conducted for
pneumococcal and influenza viruses. (Level 4)IMPACT OF ANTIHUMAN LEUKOCYTE ANTIGEN
DSAs IN KIDNEYAND LIVER TRANSPLANTATION
Problem to be Addressed
The presence of de novo donor-specific anti-HLA antibod-
ies after kidney transplantation is well documented.256,257
Improvements in immunological tools to detect anti-HLA
antibodies using single-antigen bead technology have high-
lighted that up to 20% of kidney transplant recipients
develop DSAs after kidney transplantation.180,256,257 DSAs
can cause acute AMR, chronic AMR, vascular AMR and de-
creased kidney allograft survival.256 Kidney allograft survival
is also affected by the complement-binding ability of DSAs,
with complement-binding DSAs (C1q or C3d) being associ-
ated with lower kidney allograft survival compared with
noncomplement-binding DSAs.258,259 IgG3 DSAs are also
associated with a significantly increased risk of graft loss
compared with nonIgG3 DSAs.260 Although several strate-
gies use apheresis and/or B-cell-blocking drugs and/or
complement-blocking drugs to treat acute and chronic
AMR, unfortunately there is still no established effective ther-
apy in this setting.180,261
Whereas both acute and chronic AMR have also been de-
scribed extensively after heart, lung and pancreas transplan-
tation,262 the incidence and consequences of DSAs after liverFIGURE 11. Slightly modifiable or nonmodifiable contributors to DSA otransplantation are less well established.40 Liver transplant
recipients were considered to be resistant to DSAs, so neither
the presence of preformed DSAs or de novo DSAs was con-
sidered in the routine management of these patients.263 Diffi-
culties in characterizing acute AMR, a lack of a clear
definition for chronic AMR,181,264 and the lack of specificity
of markers of complement activation (eg, C4d immunostain-
ing) are some of the challenges in evaluating the role of DSAs
in liver transplantation.263 A large retrospective study has
suggested an incidence of de novo DSAs at 1 year postliver
transplant of 8%.39 While DSAs are now identified as a risk
factor for graft rejection and are detrimental to patient sur-
vival, the full impact of DSAs postliver transplant remains
to be fully elucidated.41
For clarity, this section describes evidence for the impact of
DSAs in kidney transplantation and current knowledge on
the impact of DSAs in liver transplantation.
Impact of Anti-HLA DSAs in Kidney Transplantation
Risk Factors for the Development of DSAs
Risk factors for the development of DSAs after kidney
transplant are classified according to their detectability and
clinical factors.
Slightly Modifiable or Nonmodifiable Contributors to
DSA Occurrence
The age of the recipient (younger, usually <50 years) has
been identified as a risk factor for de novo DSAs—
potentially attributable to nonadherence.180 In addition,
there is evidence that the risk of development of de novo
DSAs is greater for deceased-donor recipients, and increased
by the presence of non-DSA antibodies before transplanta-
tion.265 An increased number of HLA mismatches are also
associated with the occurrence of DSAs.257 Although kidney
allocation algorithms aim to reduce HLA mismatches, com-
plete matching is not often feasible and the benefits of
donor/recipient HLA matching have to be balanced against
other issues, such as waiting time. Early TCMR has been
linked with the risk of development of de novo DSAs.266 In
a study of 315 consecutive renal transplants without pre-
transplant DSAs, there was a strong trend towards clinical
rejection before de novo DSA onset.257 Further risk fac-
tors for the development of de novo DSAs includeccurrence.180,257,265-267
TABLE 7.
Highly modifiable risk factors for de novo DSAs20,270,273
Cause of de novo DSA Study
Reduction or discontinuation of CNI therapy Registry studies published by Opelz et al report that dose reduction or discontinuation of cyclosporine, tacrolimus,
or MPA were associated with reduced graft survival compared with full-dose regimens
CNI-free mTORi-based immunosuppression In a prospective multicenter study, the incidence of de novo DSAs was 27.2% in everolimus-based
immunosuppression without CNIs compared with 4.9% in a CNI-based immunosuppression regimen (P = 0.001)
Nonadherence to treatment A prospective cohort study demonstrated that nonadherence to immunosuppression is a major factor for DSA
occurrence and kidney transplant failure
© 2017 Wolters Kluwer Neuberger et al S25retransplantation, and other sensitization events, such as pre-
vious pregnancy.180,267-269 Figure 11 highlights the slightly/
nonmodifiable contributors to DSA formation.Highly Modifiable Contributors to DSA Occurrence
Reduction or discontinuation of CNI therapy, CNI-free
mTORi-based immunosuppression, and nonadherence to
treatment are well-established risk factors for the occurrence
of de novo DSAs (Table 7).20,270
Nonadherence to immunosuppression is a major risk fac-
tor for the formation of DSAs.20 There are many reasons
for nonadherence, including side effects and the complexity
of treatment (pill numbers, frequency of dosing).11 More ef-
fective educational programs, better engagement of younger
recipients, and use of long-acting parenteral immunosup-
pressive therapies and once-daily drugs can be used to re-
duce the complexity of immunosuppressive regimens and
improve adherence.74,86,95,271
The long-term use of belatacept significantly reduces the
risk of de novo DSAs compared with cyclosporine A–based
immunosuppression.271 However, it is still not fully clear
whether the decreased incidence of de novo DSAs arises from
better adherence, the drug’s ability to block the second signal
and T-cell follicular helper cells, or both factors. Conversion
from twice-daily tacrolimus to once-daily prolonged-release
tacrolimus capsules intake has significantly improved adher-
ence to therapy, as assessed by electronic monitoring of drug
intake.95 However, it is unknown whether the use of once-
daily prolonged-release tacrolimus capsules is associated
with a lower incidence of DSAs compared with twice-dailyTABLE 8.
DSA assessment postkidney transplantation
Risk level Risk factor
High-risk patients Recipients with preexisting DSAs
Intermediate-risk patients Patients who have history of DSAs but are negative
for DSAs at transplantation
Low-risk patients Nonsensitized patients receiving a first kidney trans
Table based on data from Tait 2013.274tacrolimus. We are not aware of any prospective compari-
son of belatacept and tacrolimus regimens on the develop-
ment of DSAs.272
Hence, to improve kidney allograft survival, nonadherence
must be reduced. To achieve these goals,minimization strategies
and complex immunosuppressive regimens should be avoided.Detection of DSAs
DSA assessment should be done using solid-phase immu-
noassay technology.274 The reactivity of DSA should be de-
termined, and strength of reactivity expressed as mean
fluorescence intensity (MFI). Quantification of antibody level
is best achieved by titration.274 Assessment of IgG subclasses
is still not recommended. In 2013, the Transplantation Soci-
ety proposed the following guidelines (Table 8)274:
In low-risk patients with stable kidney function, although
there are no robust data to support systematic screening for
DSAs, it is done in some centers at least once in the first 3
to 12 months after transplantation. After the first year
posttransplant it is recommended that at least 1 serum sam-
ple is stored each year for patients in all risk categories, with
evaluation of current serum in the case of significant change
to an immunosuppressive regimen, suspected nonadherence,
graft dysfunction, and before transfer to a remote center.274
Currently, there is insufficient evidence to guide the man-
agement of de novo DSAs; however, kidney biopsies can be
performed in patients that develop DSAs to optimize immu-
nosuppression,274 such as targeting higher CNI trough levels,
introducing CNIs in patients on a CNI-free mTORi-based
regimen, or using B-cell blocking agents.180,270,273Frequency of monitoring
DSAs should be monitored at least once during the first 3 months
posttransplantation and a kidney biopsy should be performed,
usually at Month 3
DSAs should be monitored within the first month posttransplantation
plant Screening for DSAs should be carried out:
At least once 3 to 12 months posttransplantation
When significant change in maintenance immunosuppression
is considered (minimization/withdrawal/conversion)
When nonadherence is suspected
In cases of graft dysfunction
Before transfer to a remote center
TABLE 9.
Criteria for the diagnosis of active chronic AMR in liver allografts
Probable chronic active AMR: (all four criteria must be met) 1. Histopathological pattern of injury, both required:
a. Otherwise unexplained and at least mild mononuclear portal and/or perivenular
inflammation with interface and/or perivenular necroinflammatory activity
b. At least moderate portal/periportal, sinusoidal and/or perivenular fibrosis
2. Recent (for example, measured within 3 months of biopsy) circulating HLA DSA in serum samples
3. At least focal C4d-positive (>10% portal tract microvascular endothelia)
4. Reasonable exclusion of other insults (such as low serum complement levels, thrombocytopenia, etc)
that might cause a similar pattern of injury
Possible chronic active AMR: 1. As above, but C4d staining is minimal or absent
Table based on data from Demetris 2016.276
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AMR Postliver Transplant: Histopathological Definitions
The diagnosis of acute AMR should be based on the com-
bination of the following275:
1. DSAs in serum
2. Histopathological evidence of diffuse microvascular endothe-
lial cell injury and microvasculitis
3. Strong and diffuse C4d positivity in allograft tissue
(if available)
4. Reasonable exclusion of other causes of injury that might re-
sult in similar histological findings
A recent report from the Banff group also proposes the fol-
lowing criteria (Table 9) for diagnosis of active chronic AMR
in the liver allografts.276
Prevalence and Impact of Preformed DSAs on Graft
Function and Patient Survival
Pretransplant DSA positivity with potential clinical signif-
icance has been tentatively defined as MFI ≥5000, but stan-
dardization is still needed.276
The prevalence of preformed DSAs according to MFI
criteria was investigated in 113 consecutive ABO-compatible
liver transplants in a prospectivelymaintained transplant data-
base. Preformed DSAs were found in 67%, 32%, 25%, 19%,
16% and 9% of liver transplant recipients at MFI cutoffs of
300, greater than 1000, greater than 2000, greater than
3000, greater than 5000 and greater than 10 000, respec-
tively.277 TheMFI cutoff beyondwhich DSAsmay be consis-
tently deleterious to the liver graft is debatable. Recent data
suggest that activation of complement is observed more fre-
quently with DSA MFIs greater than 10000.278
Data from 3 studies have shown an increased risk of early
acute rejection in patients with pretransplant DSAs,277,279,280
including in patients with a very lowMFI. In addition, a high
mortality rate after living-donor liver transplantation (64%;
n = 11) was reported in patients with preformed DSAs with
MFI greater than 10 000; however, no comparisonwith a con-
trol group, nor adjustment for confounding factors was per-
formed.278 The presence of anti-class I HLA, but not class II
DSAs was associated with a significantly lower adult patient
survival at 1, 3, and 5 years post-retransplantation.281
A postliver transplant follow-up of preformed DSAs has
been investigated in 3 studies.279,280,282 These studies showed
that preformed DSAs, notably anti-class I HLAs, frequently
disappeared after liver transplantation; high preliver trans-
plant MFI was associated with high risk of persistence.279,280Persistence of preformed anti-class II DSAs withMFI greater
than 5000 was associated with an increased incidence of
acute cellular rejection, and persistence of preformed anti-
class I and/or class II DSAs with MFI greater than 5000 was
associated with reduced patient survival.279,280 Results from
other studies suggest that persistence of DSAs with high MFI
or apositive cross-match1weekpostliver transplant is associated
with an increased risk of severe graft lesions and reduced patient
and graft survival.283,284 Induction immunosuppression may
limit the consequences of sensitization in high-risk patients.284
Prevalence and Impact of De Novo DSAs on Graft
Function and Patient Survival
The incidence of de novo DSAs was reported in a retrospec-
tive study of 749 patients.39 The incidence of de novo DSAs
(MFI >5000) at 1 year was 8% and 0.4% for anti-class II
and anti-class I, respectively.39 De novo DSAs had a negative
impact on both graft and patient survival, reducing 5-year sur-
vival rates by 6% to 7%. Predictors of de novo DSA develop-
ment included cyclosporine-based immunosuppression (versus
tacrolimus) and lowCNI trough levels.39 In an update, presence
of IgG3 antibodies, antibody-fixing complement (C1q) and
de novo DSAs with MFI greater than 5000 were found to
be associated with an increased risk of mortality.285
Long-term data on the prevalence of de novo DSAs
postliver transplant are scarce. In a cross-sectional study of
patients with and without histologically proven chronic re-
jection (n = 39 each), de novo DSAs were observed in 62%
of patients with chronic rejection versus 38% without rejec-
tion (P = 0.047).286 The prevalence of de novoDSAs less than
1 year postliver transplant was significantly higher in patients
with chronic rejection compared to those without rejection
(44% vs 13%; P = 0.004).286 These data indicate that DSA
monitoring postliver transplant may be beneficial, especially
in patients in whom immunosuppression minimization is a
consideration. DSAs should also be monitored in patients
presenting with long-term graft dysfunction.
Another area in which DSAs can impact on graft function
is liver fibrosis posttransplant. Studies have suggested that, in
liver transplant recipients with no obvious cause of fibrosis,
or in patients with stable liver graft function, DSAs can pro-
mote graft fibrosis posttransplant and can accelerate fibrosis
progression in patients with HCV recurrence.280
Recommendations for Managing DSAs in
Kidney Transplantation
Routine screening for DSAs is neither universally available
nor implemented in all centers. Firm conclusions with regard
© 2017 Wolters Kluwer Neuberger et al S27to the effect on outcomes cannot be drawn in the absence
of any proven therapy. The following recommendations may
be considered where routine posttransplant DSA screening
is undertaken.1. Low immunosuppression and protocols aimed at minimizing
CNI-based immunosuppression (eg, low-dose CNI or CNI-
free therapies) are high-risk factors for the development of
de novo DSAs; the risk of these regimens should be balanced
with the potential benefit to the patient. (Level 1)
2. Simplified immunosuppressive therapies that have been
shown to enhance adherence should be used in selected
high-risk recipients. Refer to nonadherence section of this
document. (Level 2)
3. Patients should be screened for DSAs in the scenarios below
(Level 1):
◯ In cases of underimmunosuppression, for example, develop-
ment of acute cellular rejection or subclinical rejection
◯ Suspicion of nonadherence associated with graft dysfunction
4. Solid-phase immunoassay technologies, such as the single-
antigen bead assay, are able to identify DSAs not readily de-
tected using other methods, and are, therefore, favored over
other DSA detection methods. This should be supplemented
with cell-based assays to establish the potential for a positive
cross-match. (Level 2)
5. Risk stratification should be performed and the frequency of
DSA monitoring should be adjusted according to the risk
level of DSA occurrence:
◯ In high-risk patients (such as recipients with preexistingDSAs),
DSAs should be monitored in the first 3 months posttrans-
plantation and a surveillance kidney biopsy should be per-
formed at 3 months
◯ In intermediate-risk patients (such as those who have a his-
tory of DSAs but are negative for DSAs at transplantation),
DSAs should be monitored within the first month
◯ In low-risk patients (such as nonsensitized patients receiving
a first kidney transplant) with stable kidney function, al-
though there are no robust data to support systematic
screening for DSAs, it is done in some centers at least once
in the first 3 to 12 months after transplantation (Level 2)Recommendations for Managing DSAs in
Liver Transplantation
Routine screening for DSAs is neither universally available
nor implemented in all centers. There is a small, but growing
evidence base for the possible benefits of measuring DSAs in
liver transplantation, but their role remains uncertain. Firm
conclusions with regard to the effect on outcomes cannot
be drawn in the absence of any proven therapy. The follow-
ing recommendations may be considered in those centers
where DSAs are measured.
These recommendations are based on low-level evidence
from literature and expert opinion.
1. Screening for DSAs is encouraged before any attempt to
strongly minimize immunosuppression. (Level 4)
◯ If DSAs are detected (strong positive), caution is required
before further immunosuppression minimization; a liver
biopsy should be considered to ensure no silent AMR pro-
cess develops in the graft and the risk–benefit ratio of mini-
mization must be discussed
2. Screening for DSAs should also be performed in case of unex-
plained graft dysfunction. (Level 5)◯ If DSAs are detected strongly positive (MFI >5000) and the
histological pattern is consistent with chronic AMR, rein-
forcement of baseline immunosuppression must be consid-
ered, irrespective of the class of anti-HLA antibodies:
▪ Increase in CNI trough level if consistent with tolerability
▪ Introduction of mycophenolate or other agents in patients
receiving CNI monotherapy
▪ Corticosteroids in cases where the histological pattern is sug-
gestive of de novo autoimmune hepatitis with positive DSAs
▪ Further follow-up and evaluation of therapeutic changes
will be based on repetition of liver biopsy and DSA/
MFI monitoring3. In patients whose liver function tests are normal over the long
term, screening for DSAs at 1, 5 and 10 years postliver trans-
plant is proposed. (Level 5)
◯ In cases of persistent or de novo DSAs with MFI >5000:
▪Noninvasive evaluation of fibrosis or protocol biopsy is rec-
ommended for early detection of silent fibrosis progression
▪ If minimization of immunosuppression is required due to
side effects, this should be exercised with caution
◯ In the case of moderately positive DSAs (MFI, 1000-5000),
yearly screening for DSAs is suggested in addition to nonin-
vasive evaluation of fibrosisCARDIOVASCULAR COMPLICATIONS AFTER
KIDNEYAND LIVER TRANSPLANTATION
Problem to be Addressed
CVD is a leading cause of morbidity and nongraft-related
mortality in liver and kidney transplant recipients,287,288 with
heart failure (HF), coronary artery disease (CAD), and sud-
den cardiac death being the most common CVEs impacting
on transplant recipients.289,290 Prevalence of CVEs is likely
to increase in liver transplantation with the increasing num-
ber of older and higher-risk patients undergoing transplanta-
tion.291 Compared with the nondialysis general population,
age-, race-, and sex-matched kidney transplant recipients
(25-55 years) have a significantly higher CVD mortality.292
Metabolic disorders, such as diabetes, hyperlipidemia, ar-
terial hypertension and proteinuria are widely observed in
liver and kidney transplant recipients,293-295 and are risk fac-
tors for CVEs. Marked increases in these disorders are evi-
dent after both liver and kidney transplantation.296,297
With CVEs as a leading cause of death after transplanta-
tion, intervention strategies that target modifiable risk factors
for CVE (eg, obesity, diabetes, hypertension, dyslipidemia,
smoking, and renal dysfunction (such as reduced renal func-
tion or albuminuria) will be key for improving long-term out-
comes in kidney and liver transplant recipients.298-300
This section describes CVD and metabolic disorders in
kidney and liver transplant recipients, and the risk factors
for CVEs in these transplant populations. This is followed
by the management of cardiovascular risk after kidney and
liver transplantation.
CVD in Kidney and Liver Transplant Recipients
Registry data show that CVD accounts for 18% to 30% of
premature deaths among kidney transplant recipients,292 and
almost 40% of kidney transplant recipients experience a
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study, cardiovascular and cerebrovascular events, combined,
were the leading cause of death (22.9%) in the first year
postkidney transplantation, accounting for more deaths than
infection (21.6%).302 Data from observational studies suggest
particularly high frequencies of CVEs during the first few
months after kidney transplantation.303 The annual risk of
death fromCVD in kidney transplant recipientsmay be as high
as 3.5% to 5%, which is fifty times higher than that of the
general population.294
In a study of 54,697 liver transplant recipients, conducted
between 2002 and 2012, 2.9% died within 30 days; CVE
was the leading cause of 30-day mortality, accounting for
42.1% of fatalities—more than infection (27.9%) or graft
failure (12.2%).304 When a wider composite cardiovascular
end point was assessed (including atrial fibrillation [AF],
HF, and pulmonary embolism) the event rate was 8% and
11% at 30 and 90 days after liver transplantation, respec-
tively.305 AF was the major event, and was associated with
longer hospital stays, a higher incidence of acute kidney in-
jury, and lower rates of recipient and graft survival.305,306
A retrospective review of 455 consecutive liver transplant
patients has shown that despite the exclusion of high CV risk
candidates for liver transplantation, CVD occurs in 10.6% of
liver transplant recipients at 1 year, 20.7% at 5 years, and
30.3% at 8 years posttransplant.307 Fatal and nonfatal CVEs
can also persist into the second decade postliver transplant.308
Metabolic Disorders in Kidney and Liver
Transplant Recipients
Marked increases in the prevalence of metabolic disorders
(diabetes, hyperlipidemia, and arterial hypertension) are ob-
served after liver transplantation,296,297 and as many as
58% of liver transplant recipients may meet the criteria for
metabolic syndrome posttransplant (Table 10).293,309
Estimates of NODAT range up to 25% in renal transplant
recipients and 25% in liver transplant recipients, with preva-
lence increasing to 40% to 60% in HCV-infected liver trans-
plant recipients.310,311 A study of Italian kidney transplant
recipients showed that 41% had metabolic syndrome at
6 months posttransplant, demonstrating the significance of
this risk factor for the occurrence of severe CVD.312 Other
metabolic disorders, such as hypertension, affects up to
90%of kidney transplant recipients, and dyslipidemia is also
highly prevalent (Table 10).292-294
Risk Factors for CVEs in Kidney and Liver
Transplant Recipients
In general, risk factors for CVEs, for both kidney and
liver transplant recipients, can be present before transplan-
tation and posttransplantation. Pretransplant risk factorsTABLE 10.
Incidence of metabolic disorders in liver and kidney transplant re
Metabolic disorder % of liver transplant recip
Metabolic syndrome 44-58%
Diabetes (NODAT) 2.5-25%
40-60% (HCV-infected liver transpla
Dyslipidemia 45-69%
Hypertension Up to 70%for CVEs include conventional demographic (and non-
modifiable) factors, such as age (young age in kidney trans-
plantation and older age in liver transplantation), sex, race,
preexisting conditions, such as diabetes, ischemic heart dis-
ease, duration of dialysis for kidney transplant recipients,
smoking and general patient health (Figure 12).289,292,313,314
Posttransplant risk factors for CVEs include NODAT, hyper-
tension, impaired glucose tolerance,288,289,292,315 impaired
kidney function295,316 and posttransplant hyperglycemia
(Table 11 and Figure 12).317,318
In clinical trials and registry studies in kidney transplanta-
tion, hypertension shows a strong association with major ad-
verse cardiovascular event (MACE), as well as graft failure
and mortality289; increased systolic and pulse pressure—
markers of vascular stiffness—are specifically associatedwith
cardiac death and stroke.289
Other nonclassic CVE risk factors (anemia, proteinuria,
number of episodes of graft rejection, reduction in allograft
function) have also been identified in kidney transplant recip-
ients.295,319-321 Anemia has been shown to be an independent
risk factor for de novo congestive heart failure, and for all-
cause and cardiovascular mortality.319 The number of epi-
sodes of graft rejection has been linked to an increased risk
of CVE,320 while graft loss resulted in increased incidence
of noncardiovascular death, all-cause mortality, MACE and
nonfatal myocardial infarction.321 Furthermore, proteinuria
is associated with CVD, graft failure and poor patient sur-
vival among kidney transplant recipients.295
For liver transplant recipients, diabetes and hyperten-
sion are each associated with an approximate twofold
higher risk of experiencing a CVE posttransplant (multi-
variate analysis).288 In liver transplantation, diabetes has
also been linked with long-term CVD,307 with duration
of diabetes, but not hypertension or hyperlipidemia,
shown to be an independent predictor of long-termmortal-
ity due to the combination of CVE, recurrent HCV, and in-
fection.330 The evaluation of inflammatory markers also
suggests that patients are at high cardiovascular risk after
liver transplantation.328,329
In the United States, where obesity is highly prevalent,
nonalcoholic steatohepatitis (NASH) is now the second most
common indication on the waiting list for adult liver trans-
plantation, after hepatitis C.333 This rise is significant be-
cause patients transplanted for NASH are at a high risk of
CVEs. These patients have a fourfold higher risk of CVE
compared to patients transplanted for alcohol-induced
cirrhosis,332,333 and a higher risk of both early and long-
term cardiovascular mortality after liver transplantation
compared to non-NASH patients.331 Renal impairment is
the strongest predictor of postliver transplant cardiovascular
mortality amongNASH recipients,331 and preoperative renalcipients289,292,294,309-312
ients % of kidney transplant recipients
41% (at 6 months posttransplantation)
nt recipients)
2-53%
60-80%
50-90%
FIGURE 12. Risk factors for CVE after kidney transplantation. Pretransplant and posttransplant factors conferring increased cardiovascular
risk after kidney transplantation. CHF, congestive heart failure; CV, cardiovascular; LVH, left ventricular hypertrophy; PTDM, posttransplantation
diabetes mellitus. Reprinted with permission from Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and mortality after kidney
transplantation. Transpl Int. 2015;28:10–21.292
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events among patients transplanted for liver cirrhosis.324 De-
creased kidney function (as assessed by estimated GFR
[eGFR]) is an independent predictor of cardiovascular risk
among patients after liver transplantation.316
Managing Cardiovascular Risk After Transplantation
In general, modifiable risk factors for CVE after transplan-
tation should be targeted and proactively managed to im-
prove patient outcomes. Routine monitoring for CVE riskTABLE 11.
Risk factors for CVE after liver transplantation288,304,305,307,316,322-
Pretransplantation factors • Pretransplant prolonged QTc interval
• Pretransplant diastolic dysfunction
• Severe preoperative CAD
• Previous history of CVD (independen
• Cardiovascular risk score indicating m
• Preoperative renal impairment and d
Metabolic disorders • Concomitant obesity and diabetes
• Diabetes and hypertension (twofold h
• Duration of diabetes, but not hyperte
to the combination of CVE, recurrent
• Inflammatory markers
Nonalcoholic fatty liver disease • NASH which is now the second mos
after hepatitis C (fourfold higher risk
CVD mortality after liver transplantat
• Renal impairment among NASH recip
Some immunosuppressive regimens • Non–CNI-based treatment
Other risk factors • Recipient factors: age; preoperative h
portal vein thrombosis
• Donor factors: BMI
• Surgical factor: cold ischemic time (r
MELD, Model for End-Stage Liver Disease.factors in kidney and liver transplant recipients should be
performed every 3 months in the first year of transplantation
and then annually after the first year. Transplant recipients at
risk of developing cardiovascular complications should be
managed according to established guidelines.299
Educating patients in lifestyle changes, including the addi-
tion of exercise into their daily/weekly routine, reduction of
high salt intake and cessation of smoking and alcohol con-
sumption, is important tominimize the risk of cardiovascular
complications after transplantation.289,292,334-337333
, AF, and stroke
t risk factor)
oderate/severe CVD
ecreased kidney function assessed by eGFR (independent predictor of CV risk)
igher risk of CVE each)
nsion or hyperlipidemia (independent risk factor for mortality due
HCV and infection)
t common indication for liver transplant among adults on the waiting list
of NASH from 2002 to 2012). NASH recipients have increased risk of
ion
ients
ospitalization; ICU status; ventilator status; calculated MELD score;
esults from a large database analysis)
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Diabetes
Frequent monitoring of plasma glucose levels is recom-
mended, particularly soon after transplantation and in pa-
tients receiving high-dose steroid treatment for acute
rejection.301 This should be done at least every day during
the first postoperative week, during treatment with high-
dose steroids and at least 3-monthly during the first year.
A study by Choi and Kwon338 demonstrated the incidence
of NODAT is higher in patients receiving tacrolimus
(25%) compared to patients receiving cyclosporine (9.5%)
(P < 0.001). The risk of developing NODAT is increased by
5% for every 0.01 mg/kg increase in prednisolone dose.289
A hemoglobin A1c (HbA1c) assay should be used for the
monitoring of NODAT in kidney transplant patients with a
target of less than 7%.339 Both the Action to Control Cardio-
vascular Risk in Diabetes (ACCORD) and Action in Diabe-
tes and Vascular Disease: Preterax and Diamicron Modified
Release Controlled Evaluation (ADVANCE) trials have
raised concerns regarding intensive hypoglycemic therapy
in nontransplant type 2 diabetic individuals, and an HbA1c
target of 6.5% to 7.5% would be recommended in renal
transplant recipients.340,341 Table 12 summarizes the oral
hypoglycemic agents for patients with NODAT.339 A recent
study suggests that the early introduction of insulin in pa-
tients developing NODAT may actually reduce persistent di-
abetes in the longer term, although this effect remains to be
proven,342 and the use of the newer agents such as the
DPP-4 inhibitor, vildagliptin, has been shown to be safe and
effective in NODAT, without the risk of hypoglycemia.343
Management of diabetes in kidney transplant recipientsTABLE 12.
Glucose-lowering agents used in kidney transplant patients with
Class Drug
First-generation sulfonylureas All
Second-generation sulfonylureas Glipizide, Gliclazide
Gliquidone
Glibenclamide (Glyburide) Avoid
Glimepiride
Glisentide
Biguanides Metformin Avoid
Phenformin
Alpha-glucosidase inhibitors Acarbose, Miglitol Avoid
Meglitinides Repaglinide Cautious titration (s
Nateglinide Cautious u
Thiazolidinediones Pioglitazone
Rosiglitazone
Incretin mimetic Exenatide Avoid
Analog of amylin Pramlintide Avoid
DDP-4 inhibitor Sitagliptin Reduce dose to 50
25 mg (GFR <30
Vildagliptin Avoid if dialyzed, ca
(need more data)
Saxagliptin 2.5 mg d
Table reprinted with permission from Ghisdal L, Van Laecke S, Abramowicz MJ, et al. New-onset diabetes
*Potential increase in the levels of cyclosporine, tacrolimus and mTORi.
CYP, cytochrome P450; DDP-4, dipeptidyl peptidase-4.should mirror that of the general population, and follow these
guidelines.289 The management of NODAT should also in-
clude modification of immunosuppression in kidney trans-
plant patients; specifically, the minimization and possible
withdrawal of corticosteroids, with the option to switch from
tacrolimus to cyclosporine.338Dyslipidemia
Evidence from the Assessment of Lescol in Renal Trans-
plant (ALERT) trial supports the benefits of statin therapy
in kidney transplant recipients.344,345 Reductions in low-
density lipoprotein (LDL) cholesterol with fluvastatin were
associated with a reduced risk of cardiovascular endpoints,
although improvements in the primary composite outcome
(cardiac death, nonfatal myocardial infarction, or coronary
intervention) were not statistically significant.344 However,
a 2-year study extension showed significant long-term
benefits in the primary outcome.345 Kidney Disease Improv-
ing Global Outcomes (KDIGO) 2013 guidelines for lipid
management suggest prescription of statins to all kidney
transplant recipients.336 It should be noted that although
all statins have broadly similar modes of action, the poten-
tial for drug–drug interactions and toxicity varies between
statins.346 Simvastatin (and to a lesser extent atorvastatin)
may have greater interaction with CNI metabolism, resulting
in increased statin exposure and side effects, so other statins
may be preferred. Statins may cause liver dysfunction but
this is rare, and mild abnormalities of liver tests should not
preclude statin use. Myopathy may be more common with
high doses of simvastatin compared with atorvastatin or
rosuvastatin.346NODAT
Avoid/dose adjustment Drug–drug interaction
Avoid Increase cyclosporine levels
— Increase cyclosporine levels
— —
if GFR <50 mL/min per 1.73 m2 Increase cyclosporine levels
Start with 1 mg/d Increase cyclosporine levels
Avoid if advanced CKD —
if GFR <60 mL/min per 1.73 m2 —
Avoid —
if GFR <30 mL/min per 1.73 m2 —
tart 0.5 mg if GFR <40 mL/min per 1.73 m2) Increased levels of repaglinide
with cyclosporine
se if GFR <60 mL/min per 1.73 m2 Increased levels of nateglinide
with cyclosporine
Avoid if heart failure —
Avoid if heart failure —
if GFR <30 mL/min per 1.73 m2 —
if GFR <20 mL/min per 1.73 m2 —
mg/d (GFR 50-30 mL/min per 1.73 m2),
mL/min per 1.73 m2)
Metabolized by CYP3A4/5*
ution if GFR <60 mL/min per 1.73 m2 No interaction with
CYP3A4/5 substrates
aily if GFR <50 mL/min per 1.73m2 Metabolized by CYP3A4/5*
after renal transplantation: risk assessment and management. Diabetes Care. 2012;35:181–188.339
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Analyses of patients from the CTS database suggest that
control of systolic blood pressure (BP) may be associated
with improved graft, patient, and CVD-free survival.347
However, evidence from large-scale studies evaluating the
effects of antihypertensive agents in kidney transplant recip-
ients is limited. The Study on Evaluation of Candesartan
Cilexetil after Renal Transplantation (SECRET), a random-
ized, double-blind, multicenter trial evaluating the effects of
candesartan therapy on BP control and cardiovascular out-
comes, was halted prematurely owing to low event rates.348
However, it did show that candesartan provided improved
BP control and decreased proteinuria in kidney transplant
recipients compared with placebo. A recent randomized,
double-blind, placebo-controlled trial in kidney transplant
recipients with proteinuria showed no significant reduction
in the doubling of serum creatinine, end-stage renal disease,
or death, with ramipril therapy compared with placebo.349
Recent meta-analyses suggest that calcium channel blockers
should be preferred over renin-angiotensin system (RAS)
blockers for BP control, because RAS blockers are associated
with progressive worsening of renal graft function without
additional benefits in cardiovascular risk.350,351 The KDIGO
guidelines recommend a target of 130/80 mm Hg301; how-
ever, the evidence for specific BP targets is still lacking.289
Furthermore, CNIs and steroids play a major role in the
development of hypertension in kidney transplant patients;
therefore, modifications of immunosuppressive regimen may
be considered for lowering BP in these patients.292,352 The
changes in immunosuppressive drugs include CNI minimiza-
tion, conversion from cyclosporine to tacrolimus, the use of
CNI-free immunosuppressive regimens and avoiding ste-
roids.289 Although, BP control is particularly challenging in
kidney transplant patients292; in practice modification of im-
munosuppression is rarely done because of the potential risks
of acute rejection and development of DSA.39,179,289,292
Lifestyle Changes
Lifestyle changes (eg, diet, exercise, smoking cessation)
should be promoted because they can be helpful in reducing
the risk of CVE. However, there is limited evidence to sup-
port this, with the benefits of exercise shown in a small
cohort study of kidney transplant recipients.289,292
Liver Transplantation
In 2013, the American Association for the Study of Liver
Diseases (AASLD) published a practice guideline for the
long-term management of recipients after a liver trans-
plant; key points from this guidance are included in theTABLE 13.
Effect of maintenance immunosuppression on cardiovascular ris
Corticosteroids Cyclosporine Tacrolimus
Lipids ↑↑ ↑↑ ↑
Hypertension ↑↑ ↑↑ ↑
Diabetes ↑↑ ↑ ↑↑
eGFR ↔ ↓ ↓
Acute rejection ↓ ↓↓ ↓↓
Direction of arrows shows effect, with number of arrows demonstrating semi-quantitative effect. Data not ava
data from Gillis 2014 and Jardine 2011.289,362recommendation section.353 These recommendations were
based on relevant published information with the aim
of improving the long-term outcomes in adult liver
transplant recipients.
Lifestyle Changes
Educating patients in lifestyle changes, such as including
exercise into their daily/weekly routine, cessation of smoking
and (excessive) alcohol consumption, is important to mini-
mize the risk of cardiovascular complications posttransplant.
The benefit of exercise should be emphasized as this can lead
to improvements in activity levels, overall health and the abil-
ity to perform daily tasks.334 Physically active liver transplant
recipients report a better quality of life compared with
inactive patients.335
Bariatric surgery in liver transplantation may be per-
formed more frequently in the future in patients with early-
stage liver disease, to reduce weight-related CVE; however,
the efficacy of this approach requires verification by well-
designed clinical studies.354 Noninvasive endoscopic tech-
niques, such as use of the endobarrier,355,356 may be effective
and safer alternative approaches but their role in transplant
recipients has to be assessed.
Managing Cardiovascular Risk After Transplantation:
Immunosuppressive Regimen
In kidney transplantation, modifying the immunosuppres-
sive regimen may reduce the risk of hypertension, dyslipid-
emia and diabetes,289 but has yet to be endorsed by
guidelines. For example, switching from cyclosporine to ta-
crolimus has been associated with a reduction in LDL choles-
terol.357 In the Belatacept Evaluation of Nephroprotection
and Efficacy as First-line Immunosuppression Trial (BENEFIT)
and BENEFIT-EXT (extended criteria) studies, belatacept-
based regimens were associated with lower BP levels and an
improved lipid profile over the cyclosporine regimen in kid-
ney transplant recipients.358 Modeling analysis of these 2
studies suggests that the use of belatacept could lead to a
reduction in MACE of over 20%.359
In a retrospective study in liver transplant patients, ta-
crolimus use was associated with a reduced risk of CVD ver-
sus noncalcineurin-based treatment in, but not versus,
cyclosporine.307 A small randomized trial showed better
preservation of kidney function and reduction of cardiovas-
cular risk score at 1-year postliver transplantation when pa-
tients received a steroid-free regimen with tacrolimus and
MMF compared to a regimen with tacrolimus and steroids.360
A small retrospective study suggested that mTORi were not as-
sociated with an increased risk of CAD/cerebrovasculark factors in kidney and liver transplant patients
mTORi Belatacept Azathioprine Mycophenolate
↑↑ ↑ ↑↑ ↔ ↔
↑ ↔ ↔
↔ ↔
↔ ↔ ↔ ↔
↓ ↓ ↓ ↓
ilable for effect of belatacept on cardiovascular risk factors in liver transplant recipients. Table based on
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Table 13 summarizes the various effects of immunosuppres-
sive drugs on cardiovascular risk in transplant patients.289
Recommendations for Managing CVD Complications in
Kidney Transplantation
1. Ensure that patients undergo regular monitoring for risk fac-
tors for CVE after transplantation (eg, BP, lipids [at 2-3
months after transplantation and at least annually thereafter],
plasma glucose levels, HbA1c every 6 months after the first
postoperative year). (Level 5)
2. Manage risk factors for CVE according to current established
treatment guidelines. Because specific guidelines for kidney
transplant recipients are lacking, guidelines for normal individ-
uals (ie, nontransplant recipients) should be followed. (Level 5)
◯ Obesity: patients should aim to achieve a target body mass
index (BMI) of <25 kg/m2 through lifestyle changes (diet/
exercise), and the potential use of pharmacotherapy and
surgery where appropriate (Level 5)
◯ Diabetes: target HbA1C 7.0% to 7.5% using lifestyle mod-
ification, oral agents and insulin, as required (Level 5)▪ Modification of immunosuppressive regimens that cause
hyperglycemia, for example, CNI reduction and with-
drawal or avoidance of corticosteroids (when appropriate
and safe)
▪ Insulin therapy is the best choice during high-dose steroids
administration (eg, antirejection therapy); however, recipi-
ents with new-onset diabetes mellitus should be preferably
treated with oral hypoglycemic agents before insulin-based
maintenance therapy is considered
▪ Metformin or sulfonylureas may be used in kidney trans-
plant recipients with normal renal function
▪ Sulfonylureas such as glipizide and glimepiride are pref-
erable in cases of impaired renal function
3. Hypertension: BP should be controlled using lifestyle modifi-
cation and antihypertensive therapy, as required; KDIGO
2009 guidelines suggest a BP target of 130/80mmHg. (Level 5)
◯Modification of immunosuppressive regimens that cause hy-
pertension, for example, cyclosporine minimization and
withdrawal or avoidance of corticosteroids (where appro-
priate and safe)
◯ Lifestylemodifications, including reductionof salt intake, should
be implemented
◯ If lifestyle modification and a safe reduction of immunosup-
pression do not achieve target BP, antihypertensive medica-
tions should be introduced
◯Calcium channel blockers (first-line) are preferred over
RAS blockers
4. Dyslipidemia: KDIGO 2013 guidelines suggest all kidney
transplant recipients are treated with a statin (fluvastatin,
pravastatin). Target levels are: total cholesterol level
(<5.2 mmol/L [200 mg/dL]), target LDL level <2.6 mmol/L
(100 mg/dL), and target triglyceride level (<1.7 mmol/L
[150 mg/dL]). Fibrates and ezetimibe may be needed. (Level 2)
5. Educate patients on the benefits of lifestyle modification and
provide support in achieving these goals (such as dedicated
nurse practitioners). (Level 5)◯ Provide advice on healthy diet and including exercise in their
daily/weekly routine (Level 5)
◯ Provide advice on cessation of smoking and alcohol consump-
tion (Level 5)Recommendations for Managing CVD Complications
in Liver Transplantation
1. Screen high-risk patients (chronic smokers, older than
50 years, or a clinical or family history of CAD or diabetes)
preoperatively to establish risk factors for CVE (dobutamine
stress echocardiography, followed by cardiac catheterization
in case of abnormal findings). (Level 4)
2. Consider preoperative interventions for CADwhere clinically
indicated. (Level 4)
3. Ensure that patients undergo regular surveillance every
3 months in the first year and annually thereafter for risk fac-
tors for CVE (eg, BP, lipids, HbA1c). (Level 5)
4. Manage risk factors for CVE according to current established
treatment guidelines. Because specific guidelines for liver trans-
plant recipients are lacking, guidelines for normal individuals
(ie, nontransplant recipients) should be followed. (Level 5)
◯Obesity: patients should aim to achieve a target BMI of
<25 kg/m2 through lifestyle changes (diet/exercise),
and the potential use of pharmacotherapy and surgery
where appropriate
◯ Diabetes: aim to normalize target values and reestablish meta-
bolic control (fasting plasma glucose <6.7mmol/L (120 mg/dL),
peak <8.88 mmol/L (160 mg/dL) or HbA1C <7%)
▪Conversion of immunosuppression from tacrolimus to cyclo-
sporine in liver transplant recipients with poor glycemic con-
trol (persistently elevated blood glucose [>11 mmol/L] and
glycosylated hemoglobin [>9%] over a period of >6 months
despite treatment with optimal antidiabetic treatment)
▪ Insulin therapy is the best choice when high-dose steroids
are administered; however, new-onset diabetes mellitus
patients may require less insulin to control the blood glu-
cose level with time, and oral hypoglycemic agents may
be administered in cases of normal liver function
▪Metformin or sulfonylureas may be used in liver transplant
recipients with normal renal function
▪ Sulfonylureas such as glipizide and glimepiride are prefer-
able in cases of impaired renal function
◯ Hypertension: target BP should be 130/80 mm Hg
▪ Immunosuppressants that cause hypertension, such asCNIs
and corticosteroids, should be minimized
▪ Lifestyle modifications, including reduction of salt intake,
should be implemented
▪ If lifestyle modification and a reduction of immunosuppres-
sion do not achieve target BP, antihypertensive medications
should be introduced
▪ Calcium channel blockers, as well as beta-blockers, may be
effective in liver transplant recipients
▪Angiotensin-converting enzyme inhibitors, angiotensin re-
ceptor blockers, and direct renin inhibitors should be consid-
ered first-line antihypertensive therapy in liver transplant
recipients with diabetic nephropathy, chronic kidney dis-
ease and/or significant proteinuria
▪ The combination of diuretics with other classes of anti-
hypertensive medication may be effective in some liver
transplant patients
◯Hyperlipidemia: the target LDL cholesterol level is dependent
on the patient’s cardiac risk level; the target of 3.4 mmol/L
(130 mg/dL) should be reduced to 2.6 mmol/L (100 mg/dL)
or 1.8 mmol/L (70 mg/dL) for those with increasing risk
▪ Therapeutic lifestyle and dietary changes
▪ Statins
▪ Addition of ezetimibe (preference in cyclosporine-
treated patients)
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– Fish oil at 1000 mg twice daily to 4 g daily if tolerated
– Fibric acid derivatives
▪ In cases of refractory hyperlipidemia: consider changes
in immunosuppression
– Conversion from cyclosporine to tacrolimus
– CNI reduction (eg, substitute with mycophenolate)
– Replacing sirolimus with other agents
5. Educate patients on the benefits of exercise; provide advice on
including exercise in their daily/weekly routine. (Level 4)
6. Educate patients on the benefits of other lifestyle changes,
such as cessation of smoking and alcohol consumption. (Level 5)EARLY ISCHEMIC INJURYAND DGF IN KIDNEY
TRANSPLANTATION
Problem to be Addressed
Due to an increasing organ shortage, the proportion of
grafts procured fromdonors with a high KidneyDonor Profile
Index (KDPI) (>85%) has increased markedly with the inher-
ent risk of increased rates of DGF. Ischemia-reperfusion injury
(IRI) is considered an unavoidable, but potentially modifiable,
risk factor for poor long-term graft survival in solid organ
transplantation. The presence and severity of DGF is associ-
ated with inferior graft and patient survival after renal trans-
plantation.363,364 Specifically, DGF has been associated
with a 41% increased risk of graft loss and a higher mean se-
rum creatinine of 0.06 mmol/L (0.66 mg/dL) at 3.2 years of
follow-up.363 In patients with DGF >15 days, 1-year death-
censored graft survival was 79.3% versus 95.7% in patients
without DGF (P < 0.001), and 1-year patient survival was
88.86% versus 95.2%, respectively (P = 0.003).364
Prevention of Early Ischemic Injury and DGF in
Kidney Transplantation
With the marked negative impact of DGF on graft and pa-
tient survival, UNOS has released recommendations to opti-
mize the hemodynamic stability of a transplanted graft using
a variety of predefined donormanagement goals (Table 14).43,365
The implementation of these strategies in clinical practice
reduces the risk of DGF by approximately 50%.43 Such
donor management goals may, in the future, also include
pretreating donors with low-dose dopamine pretrans-
plantation to improve graft function (Table 15).366TABLE 14.
UNOS region 5, donor management goals in kidney
transplantation
Parameter Goal
Central venous pressure 4-10 mm Hg
Ejection fraction >50%
Vasopressors ≤1 and low dose*
Arterial blood gas pH 7.3-7.45
PaO2:FiO2 >300
Serum sodium 135-155 mmol/L
Blood glucose <150 mg/dL
Urine output 0.5-3 mL/kg per hour over 4 h
Mean arterial pressure 60-100 mm Hg
Recommended donor management goals to raise organ yield per donor. *dopamine≤10 μg/kg/min,
phenylephrine ≤60 μg/kg/min and noradrenaline ≤10 μg/kg/min. Table based on data from
Malinosky 2013 and Mundt 2015.43,365With the progress made in organ preservation, the use of
mild hypothermia may lower the rate of DGF in kidney
transplant recipients, especially with the use of high-risk
donors, such as donors with a high KDPI.367 Moreover, re-
cent RCTs have demonstrated a beneficial effect of hypo-
thermic machine perfusion on kidneys from all donor
types (donation after brain death, DCD, and donors with
a high KDPI), by reducing the incidence of DGF.368-370 Graft
survival rates varied among the studies, butMoers et al369 re-
ported improved 1-year graft survival in the machine-
perfusion group.368,369 A first single case report in humans
performed by Hosgood et al in 2011 and a larger case series
in 2013 demonstrated the feasibility of normothermic ma-
chine perfusion for the preservation of the kidney graft before
transplantation. Indeed, normothermic machine perfusion
may have the advantage of maintaining cellular metabolism
compared with hypothermic machine perfusion and allow
monitoring of viability, with the potential to increase the effi-
cacy of drugs administered before transplantation. Further
studies are needed to establish a clear comparison between
hypothermic and normothermic machine perfusion and
cold storage.371,372
Other areas of research include findings from a retrospec-
tive analysis that suggest combined hormonal resuscitation
(methylprednisolone, vasopressin, and triiodothyronine/L-
thyroxine) increases the yield of recovered organs.365,373
However, data on the efficacy of the individual components of
this combined technique have been negative or controversial:
for example, methylprednisolone has no effect in renal trans-
plantation, but may be beneficial in liver transplantation.365
Irish et al33 developed a validated score index based on a
multivariate analysis of data from 24 337 deceased donor re-
nal transplant recipients. Risk factors for DGF and outcomes
were studied to predict DGF and long-term outcomes at the
time of transplant.33 Based on their findings, the group cre-
ated a web-based DGF risk calculator, in which individual
or population information can be inputted to obtain a DGF
risk prediction.33 This score index has now been adopted in
a number of phase 2 trials to predict which high-risk patients
would benefit from selective interventions. These assessments
of risk for DGF may be useful tools in clinical practice in
order to select those patients who may benefit most from
new techniques and pharmaceutical interventions.
A more systematic approach to donor management with
the aim of reducing DGF is required in the future. That
means that donor management goals must be generally ap-
plied in current organ procurement, their impact must be
monitored continuously, and new additional approaches
must be introduced.365
Recommendations for Managing Early Ischemic Injury
and DGF in Kidney Transplantation
1. Donormanagement goals (see also Table 14) should routinely
include:
◯ Sufficient fluid resuscitation aiming at a central venous pres-
sure of 4 to 10mmHg; if brain death-induced central diabe-
tes insipidus (diuresis >5 mL/kg/h with specific gravity
<1005 mg/mL) is present, desmopressin should be used to
prevent polyuria (Level 2)
◯ Keeping the left ventricular ejection fraction (EF) above 50%
and the mean arterial pressure (MAP) between 60 and
100 mm Hg (Level 2 for MAP and Level 3 for EF)
TABLE 15.
Considerations for managing early ischemic injury and DGF in kidney transplantation43,365,369,373
Considerations Potential interventions
Donor management • UNOS goals (see Table 14)a
• Pretreatment of donors with low-dose dopamine (4 μg/kg per minute)
• Application of mild hypothermia
• Hypothermic machine perfusion
• Combined hormonal resuscitation
• Future research: a number of compounds are currently in clinical development, including a small interfering RNA (siRNA)
that blocks p53 and may have a positive effect on ischemia injury postkidney transplant
Recipient management • Aim for good hydration and hemodynamic stability, taking into account central venous pressure, clinical presentation
(eg, edema formation), actual body weight in comparison with dialysis “dry weight,” heart–lung X-ray findings, and MAP/heart rate
• In routine practice, avoid nephrotoxic insults where possible: NSAIDs, radio-contrast media, antibiotics (eg, vancomycin,
aminoglycosides), toxic CNI levels
a As part of the consideration for sufficient fluid resuscitation, aim at a central venous pressure of 4 to 10 mm Hg; if brain death-induced central diabetes insipidus (diuresis >5 mL/kg per hour with specific gravity
<1005 mg/mL) is present, desmopressin should be used to prevent polyuria.
siRNA, small interfering ribonucleic acid; NSAIDs, nonsteroidal anti-inflammatory drugs.
TABLE 16.
Potential risk factors associatedwithEADandnonanastomotic
BS in liver transplantation374,376,379-382
Potential risk factors for
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sors at a low dose (Level 2)
◯ Keeping laboratory parameters in the target range: arterial
pH 7.30 to 7.45, serum sodium 135 to 155 mmol/L, blood
glucose concentration less than 8.3 to 10.0 mmol/L (<150-
180 mg/dL) (Level 2)
◯ Keeping PaO2:FiO2 at >300 and urine output between 1.0
and 3.0mL/kg bodyweight (0.5 is considered to be too low)
(Level 2)
2. In addition to such donor management goals, some or all of
the following approaches will presumably be added in future
recommendations (Level 2):
◯ Pretreatment of donors with low-dose dopamine (4 μg/kg/min)
(Level 2)
◯ Application of mild hypothermia (Level 2)
◯ Hypothermic machine perfusion (Level 2)
◯ Combined hormonal resuscitation (Level 2)
3. After renal transplantation in clinical practice, a good hydra-
tion level and hemodynamic stability is aimed at, taking into
account central venous pressure, clinical presentation (eg,
edema formation), actual bodyweight in comparisonwith di-
alysis ‘dry weight’, heart–lung X-ray findings, and MAP/
heart rate. (Level 4)
4. Furthermore, nephrotoxic insults (nonsteroidal anti-
inflammatory drugs, radiocontrast media, antibiotics such
as vancomycin and aminoglycosides, toxic CNI levels) should
be routinely avoided, if possible. (Level 4)Potential risk factors for EAD nonanastomotic BS
Use of imported livers DCD
HTK as a preservation solution Donor age
High MELD scores Prolonged warm and cold ischemia time
Longer cold ischemia time Extended use of vasopressors in the donor
Recipient preoperative ventilator
statusa
DCD allograftsa
Donor agea
Allograft sizea
Degree of steatosisa
Duration of surgerya
Intraoperative transfusion
requirementsa
a Significant associations with development of EAD (P < 0.01); data from a large cohort study in 1950
consecutive primary liver transplants.
HTK, histidine-tryptophan-ketoglutarate; MELD, Model for End-Stage Liver Disease.EAD AND NONANASTOMOTIC BILIARY
STRICTURES IN LIVER TRANSPLANTATION
Problem to be Addressed
DGF is a common early complication associated with
higher risk of EAD and biliary strictures (BS), increased
hospital stay and/or hospital readmission, inferior graft
and patient survival, and increased costs.374 BS are classi-
fied according to the area of localization as anastomotic
or nonanastomotic. Anastomotic BS can usually be man-
aged endoscopically; this approach is more difficult and
less successful in patients with nonanastomotic BS. Up to
50% of patients with nonanastomotic BS, and in particular
diffuse intrahepatic BS, are not amenable to endoscopic or
surgical treatments.375EAD and BS are the end result of a cascade of tissue inju-
ries that precede transplantation (preexisting disease in the
donor, brain death-induced injury, surgical trauma, cold
preservation and warm ischemia), and culminate in IRI in
the recipient.376 The incidence of EAD in liver transplant re-
cipients ranges from 21% to 25%377; the incidence of
nonanastomotic BS is 0.5% to 10% and these account for
10% to 25%of all strictures complicating liver transplant.378
Potential Risk Factors Associated With EAD and
Nonanastomotic BS After Liver Transplantation
Liver transplantation studies have highlighted the risk fac-
tors for EAD and nonanastomotic BS (Table 16). Modifying
these risk factors and preventing organ damagemay improve
results in liver transplantation and widen its application by
increasing the pool of organs suitable for transplantation.376
Prevention of EAD and Nonanastomotic BS in
Liver Transplantation
A variety of interventions can be considered for the preven-
tion of EAD and nonanastomotic BS after liver transplantation
TABLE 17.
Considerations for managing EAD and nonanastomotic BS in liver transplantation32,384,387,388,392,395,397-402
Considerations Potential interventions
Donor management • Pretreatment of donors with steroids as standard practice
• Cold ischemia time (the period between cold flush in the donor and graft implantation in the recipient) should be kept as
short as possible, particularly for higher risk livers (DCD, steatosis)
• All periods of warm ischemia should be kept as short as possible
• Warm ischemia during procurement by: a rapid dual (aortic and portal) cold flush, an abundant use of topical cooling,
and a rapid extraction time
• Bile ducts abundantly and properly flushed during, and at the end of procurement
• HTK should be avoided for liver preservation, and University of Wisconsin/Celsior preservation solutions preferentially used
• Multi-interventional strategies (targeting simultaneously multiple pathways) still to be tested for the prevention of IRI
• Future research: hypothermic and, particularly, normothermic machine perfusion have been proven to be clinically safe and
have the potential to better preserve and assess (and resuscitate) livers, and decrease EAD and nonanastomotic BS
Recipient management • Future research: mesenchymal stem cells have been shown to enhance recovery from acute renal failure, and protect
against liver IRI in animal models
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preretrieval of the organ for transplantation, and should
continue throughout procurement, preservation of the organ,
and peritransplantation and posttransplantation.
Transplant teams classically aim to procure organs rapidly
to avoid sustained brain death-induced inflammation. Recent
studies on kidney transplantation suggest that delaying re-
trieval after brain death is beneficial for organ recovery,383 be-
cause it allows anti-inflammatory mechanisms to become
activated. Whether this strategy (‘relax and repair’ instead of
‘rush and retrieve')383 is also valid in liver transplantation is
still to be confirmed. A recent clinical trial has demonstrated
that the use of steroid therapy in deceased donors reduces
IRI and biliary injury, and improves graft function.384 The ad-
ministration of an infusion ofN-acetylcysteine before and dur-
ing procurement has also shown efficacy in improving graft
survival in liver transplantation.385
Organ manipulation, which can induce liver injury during
procurement,386 should be minimized. Rapid extraction is
necessary to prevent rewarming of the organ after perfusion,
because prolonged extraction time has been linked to early
graft failure in kidney transplantation.387 The use of a double
perfusion strategy (aortic and portal flush) is beneficial for
suboptimal livers because it reduces primary graft dysfunc-
tion and increases patient and graft survival.388 The inci-
dence of nonanastomotic BS has been reduced through the
use of low-viscosity preservation fluids, fluid pressurisation,
and the addition of urokinase to the preservation solution
in the hepatic artery.389,390 However, a recent retrospective
study has shown that flushing the liver with urokinase imme-
diately before implantation did not lead to a lower incidence
of nonanastomotic BS.391
Data from the European Liver Transplant Registry suggest
that the University ofWisconsin, Celsior and Institut Georges
Lopez-1 preservation solutions perform better than histidine-
tryptophan-ketoglutarate (HTK) solution, the latter being as-
sociated with a 10% increase in the risk of graft loss.32 A re-
cent meta-analysis has also confirmed that the University of
Wisconsin and Celsior preservation solutions result in similar
outcomes, including rates of EAD.392 The administration of a
pan-caspase inhibitor to the preservation solution has also
been shown to result in lower transaminase levels.393 In ani-
mal models, the addition of trophic factors to preservationsolutions may also improve organ function immediately
posttransplant.394 For low- and normal-risk organs, cold
storage may be suitable, but the time taken to reach 4 °C
and the low, yet persistent, level of metabolism at this temper-
ature can cause tissue trauma in the absence of oxygen. Con-
versely, towards the end of cold storage, retrograde oxygen
perfusion may actually reduce EAD.395,396
Recently, organ preservation has been revolutionized by
the development of hypothermic machine perfusion and nor-
mothermic machine perfusion. In normothermic machine
perfusion, the liver is kept viable ex situ by perfusion with
warm oxygenated blood.395,399 Mild hypothermia may
lower the rate of DGF in kidney transplantation recipients,
especially if high-risk donors, such as donors with a high
KDPI, are used.367
In a study of hypothermic machine perfusion in 31 adults
receiving livers from donors with a high KDPI, EAD was
lower in this group (19%) compared to the static cold storage
control group (30%), with significantly less biliary complica-
tions (4 vs 13; P = 0.016).397 Reperfusion injury is also rare in
these machine-perfused DCD livers.398
Liver studies in animal models are ongoing. In a porcine
model, continuous hypothermic machine perfusion reduced
hepatocyte injury but also led to an increase in Kupffer and
sinusoidal endothelial cell activation, which can eventually
result in poor long-term graft survival.403 However, im-
proved results may be achieved through the use of postcold
storage hypothermic machine perfusion.404 The big ques-
tion is whether hypothermic machine perfusion techniques
reduce the incidence of nonanastomotic BS. Studies in pigs
and rats have shown a reduction in arteriolo-necrosis of
the peribiliary plexus405 and reduced intrahepatic biliary fi-
brosis,406 but these results require verification in RCTs. A
recent study in rats reported that normothermic machine
perfusion provided better preservation of bile duct epithelial
cell function and morphology in both DCD, and non-DCD
livers (after 3 hours, followed by 2 hours ex vivo reperfu-
sion), compared with static cold storage.399 Another study
using continuous normothermic machine perfusion from
procurement to transplantation in pig liver transplants re-
sulted in good posttransplantation survival, even after
20 hours of warm preservation.400 The use of continuous
perfusion is thought to be necessary because normothermic
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Ongoing trials will hopefully answer whether this strategy
can reduce the incidence of EAD and nonanastomotic
BS.400 With advances in the understanding of the etiol-
ogy of nonanastomotic BS, machine perfusion may be best
placed to provide a better protective effect during donor
liver preservation.407
Organ management in the recipient is especially important
when attempting tomitigate IRI. Currently, there is uncertainty
as to whether the use of erythropoietin derivatives is benefi-
cial408; however, the use of antiselectins does appear to reduce
IRI after liver transplantation,409 and inhaled nitric oxide can
be used to recover liver function posttransplantation.410
In conclusion, EAD and nonanastomotic BS remain major
risk factors for poor graft survival in liver transplantation.
However, certain known risk factors can be adjusted and in-
terventions can be used to mitigate them in clinical practice.
Some strategies are already available, and should be part of
the standard of care for patients, and some are in develop-
ment, but it is important that interventions be applied at each
step of the transplantation process.
Recommendations for Managing EAD and
Nonanastomotic BS in Liver Transplantation
1. EAD and nonanastomotic BS should be prevented by targeting
all the factors related to all stages of liver transplantation, from
preretrieval of the organ, through to procurement, preserva-
tion of the organ, and posttransplantation. (Level 4)
2. Donor pretreatment with corticosteroids should be standard.
(Level 2)
3. Cold ischemia time (the period between cold flush in the do-
nor and graft implantation in the recipient) should be kept
as short as possible, particularly for higher-risk livers (DCD,
steatosis, etc). (Level 3)
4. All periods of warm ischemia should be kept as short as pos-
sible. (Level 4)
◯ Warm ischemia in DCD donors
◯ Warm ischemia during procurement by:
▪ a rapid dual (aortic and portal) cold flush
▪ an abundant use of topical cooling, and
▪ a rapid extraction time, and
◯ Finally, a short implantation time in the recipient (Level 5)
5. Bile duct should be abundantly and properly flushed during
and at the end of the procurement. (Level 2)
6. HTK should be avoided for liver preservation. (Level 3)
7. Multi-interventional strategies (simultaneously targetingmul-
tiple pathways) will have to be tested for the prevention of
IRI. (Level 4)
8. Hypothermic and, particularly, normothermic machine per-
fusion have proven to be clinically safe and have the potential
to better preserve and assess (and resuscitate) livers, and de-
crease EAD and nonanastomotic BS. (Level 3)CONCLUSION AND CALLTO ACTION
Patient and graft outcomes continue to improve in the
short-term postkidney or postliver transplant, with survival
rates now at over 80% at the 1-year mark. Unfortunately,
there are still challenges remaining that negatively affect
longer-term prognosis of these individuals. Improving themaintenance of grafts and health of patients would not only
improve quality of life, but would also reduce the need for
retransplantation and thus increase the number of organs
available for transplant. The clinical transplant community
needs to identify and manage those patient factors which
are within its control to modify, to decrease the risk of graft
failure and improve longer-term outcomes.
There are many risk factors for graft loss. Modifiable risk
factors influencing the longer-term maintenance of the graft
and patient include nonadherence, IPV, underimmunosup-
pression, adverse effects due to immunosuppression, DSAs,
and cardiovascular and metabolic complications. With this
guidance document and checklist, the COMMIT group have
provided practical recommendations for both the identifica-
tion and management of these modifiable risk factors
postkidney and postliver transplant. It is hoped that these rec-
ommendations will become a routine part of the posttrans-
plantation management paradigm to maximize the life of
the graft and patient.
Some strategies to manage risk are already available, and
should be part of the standard of care for patients, and some
are still in development. For others, such as DSAs, emerging
evidence will help to fully establish the implications on
long-term outcomes. Nevertheless, it is important that the in-
terventions are applied at each step of the transplantation
process in order to improve graft and patient outcomes for
both kidney and liver transplants in the long as well as the
short term.
The field of transplantation will undoubtedly benefit from
research, which will result in better understanding the immu-
nological mechanisms of graft rejection. It will also lead to
improved use of immunosuppression, which will promote
tolerance and reduce or even abolish the need for long-term
treatment with immunosuppressive agents, and so reduce as-
sociated adverse effects. Improved management of the donor
and improved preservation techniques, with the development
of validated biomarkers to identify viable organs and to help
guide immunosuppression, will increase the number and qual-
ity of organs for transplantation. Although the future looks
promising for the field of transplantation, recipients and
HCPs must not lose sight of those factors that can be modi-
fied today, so leading to the best possible future outcomes
for the recipients, and giving consolation to the donor family.ACKNOWLEDGMENTS
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POST-KIDNEY TRANSPLANT PATIENT CARE CHECKLIST 
This checklist is intended to help the clinician in the management of modifiable risk factors for graft loss in 
kidney transplant patients over 1 year post-transplant and should be used in conjunction with local guidelines.
Patient name:
Patient ID:            DOB:
Gender:
Indication for transplant:
Date of transplant: 
    Left kidney      Right kidney
    Presence of preformed antibodies
    Presence of de novo DSAs     Re-transplant
Other relevant comorbidities (e.g. HIV infection,  
combined transplant, previous PTLD/cancer): 
 
BEFORE YOU SEE THE PATIENT
    Review the patient’s immunosuppressive regimen, 
concomitant medication and over-the-counter 
medications
    Review immunosuppression serum trough levels over  
the previous year and identify any significant variation
    Review BMI, BP, fasting plasma glucose and  
renal function
   Document any known risk factors for non-adherence: 
 
    Each year, consider immunisation status, 
cardiovascular status and cancer surveillance 
 
CLINICAL VARIABLES
(This checklist is intended to be used in addition to the 
biochemistry and serology lab report for the patient):
BP:                            /      mmHg                 
HR:                            /min          Weight:                            kg
Height:                          m           BMI:                           kg/m2
Current smoker:              Number per day:
Average alcohol intake:                          units/week
 
Medication:
Immunosuppressant doses and levels:   
 
Drug Level Corresponding  
daily dose
ng/mL /day
ng/mL /day
ng/mL /day
Other: 
 
Latest renal allograft biopsy report (when applicable): 
 
Yes No
 
Everolimus
 Tacrolimus
Mycophenolate
Cyclosporine Sirolimus
Corticosteroids
Azathioprine 
© 2017 Wolters Kluwer Neuberger et al S46
2
TP500951
REVIEW IMMUNOSUPPRESSION
1. IS THE PATIENT EXPERIENCING 
ANY IMMUNOSUPPRESSIVE  
DRUG-RELATED ADVERSE  
EFFECTS OR SYMPTOMS?
e.g. tremor, headache, hypertension, renal impairment, 
diabetes, infection, malignancy
    No – continue with annual screening listed below.
    Yes – investigate appropriately. Consider underlying  
factors and treat accordingly. Investigate trough levels 
and immunosuppressive regimen. Consider whether 
beneficial changes can be made.
Annually:
    If appropriate, request a yearly abdominal ultrasound 
examination to detect intra-abdominal tumours 
(especially renal cell carcinoma of the native kidney)
    Enquire if the patient has been attending routine 
surveillance programmes for prostrate, breast,  
cervical and colon cancer as appropriate
If no –  educate the patient on the importance of this 
and refer appropriately.
    Conduct surveillance of skin cancers 
If no – educate them on the importance of routine self-
examination/inspection and refer to dermatologist if the 
patient has a suspicious lesion. Consider annual review 
based on local practice.
    Does the patient have unexplained gastrointestinal 
symptoms?
If yes – request an endoscopy.
    Consider sexual and reproductive health (especially 
teratogenic effect of some immunosuppressive drugs)  
and discuss family planning
    Consider bone health: if at risk of osteoporosis, consider 
a DEXA scan and provide supplements such as calcium 
and vitamin D or treatment such as bisphosphonates 
    Has the eGFR persistently decreased and/or fallen below 
45mL/min/m2 (CKDT3B) and/or is proteinuria present?
If yes – consider performing a renal ultrasound and/or 
renal biopsy.
    Cardiovascular check-up (e.g. cardiac ultrasound, 
stress test, arterial Doppler, etc)
    Any other relevant comorbid condition should be 
assessed or referred appropriately at least once 
yearly (e.g. diabetes mellitus, respiratory diseases, 
ophthalmic disorders, neurological diseases, etc)
2. CARDIO- AND CEREBRO-  
VASCULAR AND METABOLIC  
COMPLICATIONS
    Encourage regular exercise (at least 150 minutes  
per week, 10,000 steps/day)
    Encourage cessation of smoking (if indicated, 
refer to respiratory specialist team for coaching)
    Review alcohol consumption and advise/refer if 
appropriate (e.g. psychologist, alcohol counsellor)*
    Check BP, blood sugar and cholesterol concentrations
      
•   Consider statins (e.g. fluvastatin), anti-hypertensives  
(e.g. calcium channel blockers) and glucose-lowering agents 
    Encourage maintaining an adequate weight (BMI <25kg/m2)
    Provide dietary information and/or support
    Establish allied health professional team support for 
lifestyle adjustment
    Annual cardiovascular check-up (e.g. ECG)
Follow guidelines for general population. If BMI, BP, 
glucose, HbA1c or low-density lipoprotein cholesterol are 
outside of normal range, consider underlying factors and 
provide patient education as necessary. Consider referral  
to cardiovascular specialist.
  Is the serum trough 
level within the  
desired range?
    Yes – continue to adhere to target 
immunosuppression levels, or consider 
a carefully monitored minimisation 
regimen if deemed clinically 
appropriate
    No – above therapeutic range
    Is this a true trough level?  
(check correct dosing time and 
sampling time)
    Be aware of potential 
immunosuppressive drug-related 
adverse effects See section 1
    Be aware of patients overdosing 
to compensate for non-adherence
Non-adherence 
See section 3
Intra-patient variability
Consider:
    Drug–drug interactions
    Food intake
    Generic substitution
    Gastrointestinal causes
    Non-adherence 
See section 4
Review the 
immunosuppression regimen
    No – below therapeutic range 
Consider the possible causes
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3. STRATEGIES FOR MANAGING 
NON-ADHERENCE
The ‘fifth’ vital sign post-transplantation. Non-adherence 
to immunosuppressive regimen is a common and 
independent risk factor for poor clinical outcomes.
Drug-adherence monitoring:
    Monitor prescription refills, patient self-report,  
pill counts, assess intra-patient variability over time  
(use new digital technology/electronic monitoring  
where appropriate/available)
Collaborative assessment (if clinically 
indicated):
    Psychologists
    Nursing staff
    Pharmacists
Self-reporting:
    BAASIS© or IMAB questionnaire
    Other validated self-reporting questionnaires
Patient-level intervention:  
    Consider a more simplified regimen  
(e.g. monotherapy, once-daily dosing)
    Provide clear, printed medication instructions and 
medication schedules at an appropriate level for the 
patient’s health literacy
    Encourage counselling/behavioural intervention (e.g. 
use of a pill box, reminders, motivational interview)
    Engage with the pharmacy team for help and support  
around adherence
   Involve family and the use of specialised support groups
4. INTRA-PATIENT VARIABILITY
    Has the patient been experiencing gastrointestinal 
events?
If yes – increase trough-level monitoring frequency 
(weekly if high risk) and investigate underlying factors or 
refer to gastrointestinal specialist as required. Consider  
prolonged-release dosing of immunosuppressant(s).
    Does the patient follow dietary advice  
(no grapefruit juice, avoid herbal products, etc)?
If no – increase trough-level monitoring frequency and 
encourage a healthy diet. Provide patient education or  
refer to a dietician or specialist nurse as required.
    Is there a potential drug–drug interaction? 
If yes – correct as necessary, avoiding any potential 
interactions. 
    Has there been a recent switch to a generic substitute? 
If yes – return to prescribing the original drug regimen and 
increase trough-level monitoring frequency (weekly if high 
risk) until the variability is not clinically relevant.
    Has there been an episode of kidney graft 
dysfunction?
If yes – increase trough-level monitoring frequency (weekly  
if high risk) and correct the underlying factors if possible.
5. DE NOVO DONOR-SPECIFIC  
ANTIBODIES (DSAs)  
The role of DSAs is not fully understood but it is  
worth considering, especially:
    Before considering minimising immunosuppression
    With unexpected graft dysfunction  
(e.g. after immunosuppression minimisation)
   With any type of rejection (clinical, subclinical, chronic)
    In patients with preformed DSAs:
       •   DSAs should be tested for in the first 3 months  
post-transplant (ideally with a protocol renal  
biopsy at 3 months)
    In patients without preformed antibodies:
       •   DSAs should be tested for once between  
3–12 months post-transplant
    In patients with de novo DSA formation:
       •   DSAs should be checked for as indicated  
and after adjustment of immunosuppressive 
regimen
    Suspicion of non-adherence associated with  
graft dysfunction 
DSAs can be monitored through specific assays  
(e.g. single-antibody bead assay).
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GUIDELINES
This checklist is intended to help the clinician in the 
management of modifiable risk factors for graft loss 
in kidney transplant recipients. It has been developed 
specifically for use with adult kidney transplant recipients 
during routine monitoring at 1 or more years post-transplant.
How to use the checklist:
This checklist can be used by clinicians in more than  
one way, with the optional step of tick boxes. It is  
intended to be suitable for use:
–   In booklet form, as part of a patient’s medical notes, 
to act as a useful guide before and during a patient 
consultation
–   As an A3 wall poster (centre pages), providing 
generalised information on modifiable risk factors to be 
aware of during routine care post transplantation
Useful links:
http://www.riskfactorcalculator.eu/ 
(BAASIS© questionnaire, renal function calculator,  
variability calculator)
https://www.uea.ac.uk/pharmacy/research/imab-q/quest 
(IMAB questionnaire)
http://www.rxlist.com/drug-interaction-checker.htm  
(Drug–drug interaction checker)
http://www.cdc.gov/healthyweight/assessing/bmi/adult_
bmi/metric_bmi_calculator/bmi_calculator.html  
(BMI calculator)
http://www.drinkingandyou.com/site/pdf/
Sensibledrinking.pdf (Alcohol consumption guidelines)
https://www.gov.uk/government/uploads/system/
uploads/attachment_data/file/545937/UK_CMOs__
report.pdf (Alcohol consumption guidelines)
Abbreviations:
BAASIS© – Basel Assessment of Adherence to 
Immunosuppressive Medication Scale
CKDT3B – Stage 3B chronic kidney disease (moderately 
reduced kidney function) in renal transplant recipient
DSA – Donor-specific antibodies
IMAB – Identification of Medication Adherence Barriers 
PTLD – Post-transplant lymphoproliferative disorder
TX/16/0018/APEL March 2017
Disclaimers and development process:
The checklist should be used in conjunction with local guidelines and should not replace clinical judgment. It is intended 
to be used as a clinical aid, rather than a comprehensive protocol.
*Alcohol consumption policies will vary between transplant units and some patients should not drink alcohol. The recommendation of safe drinking varies 
between countries in healthy non-transplant adults. For liver transplant patients, advice on alcohol consumption will vary by indication.
Multi-level risk factors for non-adherence to immunosuppressive regimens
Risk factor Examples
Sociodemographic factors •   Adolescence, senior patient age (e.g. when cognitively impaired)
•  Lack of social support
•  Non-white race
Patient-related factors •  Previous non-adherence
•  Disturbing side-effects
•  Barriers: busy lifestyle, interruption of daily routine
•  Forgetfulness
•  Inadequate health beliefs
•  History of substance abuse
Treatment-related factors •   Higher complexity and longer duration of the drug regimen,  
number of prescribed pills
•  Taste and size of the pill
Condition-related factors •  Depressive symptomatology
Healthcare teams and systems factors •  Lack of adherence assessment as part of regular transplant follow-up
•  Lack of adherence support as part of transplant follow-up
•  Lack of coverage of immunosuppressive drugs
•   Healthcare professionals not trained in behavioural assessment and 
interventions, or adequate communication style
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POST-LIVER TRANSPLANT PATIENT CARE CHECKLIST
This checklist is intended to help the clinician in the management of modifiable risk factors for graft loss in 
liver transplant patients over 1 year post-transplant and should be used in conjunction with local guidelines. 
Patient name:
Patient ID:            DOB:
Gender:
Indication for transplant:
Date of transplant: 
 
Type of transplant: (e.g. whole, split, donation after 
cardiac death, donation after brain death) 
 
Other relevant comorbidities: 
 
BEFORE YOU SEE THE PATIENT 
    Review the patient’s immunosuppressive regimen, 
concomitant medication and over-the-counter 
medications
    Review immunosuppression serum trough levels over 
the previous year and identify any significant variation
    Review BMI, BP, fasting plasma glucose and renal 
function
   Document any known risk factors for non-adherence: 
 
    Each year, consider immunisation status, 
cardiovascular status, cancer surveillance  
CLINICAL VARIABLES
(This checklist is intended to be used in addition to the 
biochemistry and serology lab report for the patient)
BP:                            /      mmHg                 
HR:                              /min         Weight:                           kg
Height:                            m         BMI:                            kg/m2
Current smoker:                 Number per day:
Average alcohol intake:                            units/week
 
Medication:
Immunosuppressant doses and levels:  
 
Drug Level Corresponding  
daily dose
ng/mL /day
ng/mL /day
ng/mL /day
Other: 
Yes No
 
Everolimus
Tacrolimus
Mycophenolate
Cyclosporine Sirolimus
Corticosteroids
Azathioprine 
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REVIEW IMMUNOSUPPRESSION
1. IS THE PATIENT EXPERIENCING 
ANY IMMUNOSUPPRESSIVE  
DRUG-RELATED ADVERSE  
EFFECTS OR SYMPTOMS?
e.g. tremor, headache, hypertension, renal impairment, 
diabetes, infection, malignancy
    No – continue with annual screening listed below.
    Yes – investigate appropriately. Consider underlying 
factors and treat accordingly. Investigate trough levels 
and immunosuppressive regimen. Consider whether 
beneficial changes can be made.
Annually:
    Is the patient high risk for head and neck or lung 
cancers (alcohol/smoking)?
If yes – conduct a physical examination, including the 
oropharynx. If >50 years and symptomatic also consider a  
low-dose CT scan or chest X-ray. 
If no – conduct a physical examination, including the 
oropharynx.
    Enquire whether the patient has been attending 
routine surveillance programmes for prostate, breast, 
cervical and colon cancer as appropriate
If no – educate the patient on the importance of this  
and refer appropriately.
    Conduct surveillance of skin cancers 
If no – educate them on the importance of routine self-
examination/inspection and refer to dermatologist if the 
patient has a suspicious lesion. Consider annual review 
based on local practice.
    Does the patient have unexplained gastrointestinal 
symptoms?
If yes – request an endoscopy.
    Consider sexual and reproductive health (especially 
teratogenic effect of some immunosuppressive drugs)  
and discuss family planning
    Consider bone health: if at risk of osteoporosis, 
consider a DEXA scan and provide supplements 
such as calcium and vitamin D or treatment such as 
bisphosphonates 
    Has the eGFR persistently decreased and/or fallen  
below 45mL/min/m2 (CKDT3B)?
If yes – consider performing a renal ultrasound, referral to  
renal specialist and/or renal biopsy.
    Cardiovascular check-up (e.g. cardiac ultrasound,  
stress test, arterial Doppler, etc)
    Any other relevant comorbid condition should be  
assessed or referred appropriately at least once 
yearly (e.g. diabetes mellitus, respiratory diseases, 
ophthalmic disorders, neurological diseases, etc)
  Is the serum trough 
level within the  
desired range?
    Yes – continue to adhere to 
target immunosuppression levels, 
or consider a carefully monitored 
minimisation regimen if deemed 
clinically appropriate
    No – below therapeutic range 
Consider the possible causes
    No – above therapeutic range
    Is this a true trough level? 
(check correct dosing time 
and sampling time)
    Be aware of potential 
immunosuppressive 
drug-related adverse effects 
See section 1
    Be aware of patients 
overdosing to compensate 
for non-adherence
Non-adherence 
See section 3
Intra-patient variability
Consider:
    Drug–drug interactions
    Food intake
    Generic substitution
    Gastrointestinal causes
    Non-adherence 
See section 4
Review the immunosuppression 
regimen
S51 Transplantation www.transplantjournal.com
TP500951
■ ■ Volume 101 ■ Number 4April 2017
2. CARDIO- AND CEREBRO-  
VASCULAR AND METABOLIC  
COMPLICATIONS
    Encourage regular exercise (at least 150 minutes  
per week, 10,000 steps/day)
    Encourage cessation of smoking (if indicated,  
refer to respiratory specialist team for coaching)
    Review alcohol consumption and advise/refer if 
appropriate (e.g. psychologist, alcohol counsellor)*
    Check BP, blood sugar and cholesterol concentrations
      •   Consider statins (e.g. fluvastatin), anti-hypertensives 
(e.g. calcium channel blockers) and glucose-lowering 
agents 
    Encourage maintaining an adequate weight  
(BMI <25kg/m2)
    Provide dietary information and/or support
    Establish allied health professional team support  
for lifestyle adjustment
    Annual cardiovascular check-up (e.g. ECG)
Follow guidelines for general population. If BMI, BP, glucose, 
HbA1c or low-density lipoprotein cholesterol are outside 
of normal range, consider underlying factors and provide 
patient education as necessary. Consider referral  
to cardiovascular specialist.
3. STRATEGIES FOR MANAGING 
NON-ADHERENCE
The ‘fifth’ vital sign post-transplantation. Non-adherence 
to immunosuppressive regimen is a common and 
independent risk factor for poor clinical outcomes.
Drug-adherence monitoring:
    Monitor prescription refills, patient self-report,  
pill counts, assess intra-patient variability over time 
(use new digital technology/electronic monitoring 
where appropriate/available)
Collaborative assessment (if clinically indicated):
    Psychologists
    Nursing staff
    Pharmacists
Self-reporting:
    BAASIS© or IMAB questionnaire
    Other validated self-reporting questionnaires
Patient-level intervention:  
    Consider a more simplified regimen  
(e.g. monotherapy, once-daily dosing)
    Provide clear, printed medication instructions and 
medication schedules at an appropriate level for the 
patient’s health literacy
    Encourage counselling/behavioural intervention (e.g. 
use of a pill box, reminders, motivational interview)
    Engage with the pharmacy team for help and support 
around adherence
    Involve family and the use of specialised support groups
4. INTRA-PATIENT VARIABILITY
    Has the patient been experiencing gastrointestinal 
events?
If yes – increase trough-level monitoring frequency  
(weekly if high risk) and investigate underlying factors  
or refer to gastrointestinal specialist as required.  
Consider prolonged-release dosing of 
immunosuppressant(s).
    Does the patient follow dietary advice  
(no grapefruit juice, avoid herbal products, etc)?
If no – increase trough-level monitoring frequency and 
encourage a healthy diet. Provide patient education or  
refer to a dietician or specialist nurse as required.
    Is there a potential drug–drug interaction? 
If yes – correct as necessary, avoiding any potential 
interactions. 
    Has there been a recent switch to a generic substitute? 
If yes – return to prescribing the original drug regimen and 
increase trough-level monitoring frequency (weekly if high 
risk) until the variability is not clinically relevant.
   Has the patient experienced a liver graft event?
If yes – increase trough-level monitoring frequency (weekly if 
high risk) and correct the underlying factors if possible.
5. DE NOVO DONOR-SPECIFIC  
ANTIBODIES (DSAs)  
The role of DSAs is not fully understood but it is  
worth considering, especially:
    Before considering minimising immunosuppression
    With unexpected graft dysfunction 
    With any type of rejection (clinical, subclinical, chronic)
    In all patients at 1, 5 and 10 years post-transplant
DSAs can be monitored through specific assays  
(e.g. single-antibody bead assay).
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GUIDELINES
This checklist is intended to help the clinician in the 
management of modifiable risk factors for graft loss in liver 
transplant recipients. It has been developed specifically 
for use with adult liver transplant recipients during routine 
monitoring at 1 or more years post-transplant.
How to use the checklist:
This checklist can be used by clinicians in more than one 
way, with the optional step of tick boxes. It is intended to 
be suitable for use:
–   In booklet form, as part of a patient’s medical notes, 
to act as a useful guide before and during a patient 
consultation
–   As an A3 wall poster (centre pages), providing 
generalised information on modifiable risk factors to  
be aware of during routine care post-transplantation
Useful links:
http://www.riskfactorcalculator.eu/  
(BAASIS© questionnaire, renal function calculator,  
variability calculator)
https://www.uea.ac.uk/pharmacy/research/imab-q/quest 
(IMAB questionnaire)
http://www.rxlist.com/drug-interaction-checker.htm  
(Drug–drug interaction checker)
http://www.cdc.gov/healthyweight/assessing/bmi/adult_
bmi/metric_bmi_calculator/bmi_calculator.html  
(BMI calculator)
http://www.drinkingandyou.com/site/pdf/
Sensibledrinking.pdf (Alcohol consumption guidelines)
https://www.gov.uk/government/uploads/system/
uploads/attachment_data/file/545937/UK_CMOs__
report.pdf (Alcohol consumption guidelines)
Abbreviations:
BAASIS© – Basel Assessment of Adherence to 
Immunosuppressive Medication Scale
CKDT3B – Stage 3B chronic kidney disease  
(moderately reduced kidney function)
DSA – Donor-specific antibodies
IMAB – Identification of Medication Adherence Barriers 
TX/16/0018/APEL March 2017
Disclaimers and development process:
The checklist should be used in conjunction with local guidelines and should not replace clinical judgment. It is intended 
to be used as a clinical aid, rather than a comprehensive protocol.
Multi-level risk factors for non-adherence to immunosuppressive regimens
Risk factor Examples
Sociodemographic factors •   Adolescence, senior patient age (e.g. when cognitively impaired)
•  Lack of social support
•  Non-white race
Patient-related factors •  Previous non-adherence
•  Disturbing side-effects
•  Barriers: busy lifestyle, interruption of daily routine
•  Forgetfulness
•  Inadequate health beliefs
•  History of substance abuse
Treatment-related factors •   Higher complexity and longer duration of the drug regimen,  
number of prescribed pills
•  Taste and size of the pill
Condition-related factors •  Depressive symptomatology
Healthcare teams and systems factors •  Lack of adherence assessment as part of regular transplant follow-up
•  Lack of adherence support as part of transplant follow-up
•  Lack of coverage of immunosuppressive drugs
•   Healthcare professionals not trained in behavioural assessment and 
interventions, or adequate communication style
*Alcohol consumption policies will vary between transplant units and some patients should not drink alcohol. The recommendation of safe drinking varies 
between countries in healthy non-transplant adults. For liver transplant patients, advice on alcohol consumption will vary by indication.
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ADVAGRAFTM 0.5 mg, 1 mg, 3 mg and 5 mg Prolonged-
release hard capsules (tacrolimus) PROGRAFTM 0.5 mg,
1 mg and 5 mg hard capsules (tacrolimus)
Presentations: ADVAGRAF Prolonged-release hard cap-
sules containing tacrolimus 0.5 mg, 1 mg, 3 mg and 5 mg
PROGRAF hard capsules containing tacrolimus 0.5 mg, 1
mg and 5 mg. Indications: ADVAGRAF and PROGRAF:
Prophylaxis of transplant rejection in adult liver or kidney al-
lograft recipients and treatment of allograft rejection resis-
tant to treatment with other immunosuppressive medicinal
products. Posology and Administration: ADVAGRAF and
PROGRAF therapy require careful monitoring by adequately
qualified and equipped personnel. Either drug should only be
prescribed, and changes in immunosuppressive therapy initi-
ated, by physicians experienced in immunosuppressive ther-
apy and the management of transplant patients. Dosage
recommendations given below should be used as a guideline.
ADVAGRAF or PROGRAF are routinely administered in
conjunction with other immunosuppressive agents in the ini-
tial post-operative period. The dose may vary depending on
the immunosuppressive regimen chosen. Dosing should be
based on clinical assessments of rejection and tolerability
aided by blood level monitoring. To suppress graft rejection
immunosuppression must be maintained so no limit to the
duration of oral therapy can be given. The daily dose of
ADVAGRAF capsules should be taken once daily in the
morning with fluid (preferably) water at least 1 hour before
or 2-3 hours after a meal. PROGRAFcapsules should
be taken as for ADVAGRAF, in two divided doses.
ADVAGRAF: In stable patients converted from PROGRAF
(twice daily) to ADVAGRAF (once daily) on a 1:1 (mg:mg)
total daily dose basis the systemic exposure to tacrolimus
for ADVAGRAF was approximately 10% lower than
for PROGRAF. The relationship between tacrolimus trough
levels (C24) and systemic exposure (AUC0-24) for
ADVAGRAF is similar to that of PROGRAF. When
converting from PROGRAF capsules to ADVAGRAF trough
levels should be measured before and within two weeks after
conversion. In de novo kidney and liver transplant patients
AUC0-24 of tacrolimus for ADVAGRAF on Day 1 was 30%
and 50% lower respectively, when compared with that for the
immediate release capsules (PROGRAF) at equivalent doses.
By Day 4, systemic exposure as measured by trough levels is
similar for both kidney and liver transplant patients with both
formulations. Race: In comparison to Caucasians, black pa-
tients may require higher tacrolimus doses to achieve similar
trough levels. Prophylaxis of transplant rejection – liver
and kidney: Initial dose of ADVAGRAF and PROGRAF cap-
sules is 0.10-0.20 mg/kg/day for liver transplantation and
0.20-0.30 mg/kg/day for kidney transplantation starting ap-
proximately 12-18 hours for ADVAGRAF and 12hrs for
PROGRAF after completion of liver or within 24 hours of
completion of kidney transplant surgery. Dose adjustment
post-transplant: ADVAGRAF and PROGRAF doses are usu-
ally reduced in the post-transplant period. It is possible in
some cases to withdraw concomitant immunosuppressive
therapy leading to ADVAGRAF monotherapy or PROGRAF
dual therapy ormonotherapy. Post-transplant improvement in
the condition of the patient may alter the pharmacokinetics
of tacrolimus and may necessitate further dose adjustments.
Dose recommendations – Conversion to ADVAGRAF. Pa-
tients maintained on twice daily PROGRAF requiring con-
version to once daily ADVAGRAF should be converted on
a 1:1 (mg:mg) total daily dose basis. Following conversion,
tacrolimus trough levels should be monitored and if neces-
sary dose adjustments made. Care should be taken when
converting patients from ciclosporin-based to tacrolimus-
based therapy. Initiate ADVAGRAF after considering
ciclosporin blood concentrations and clinical condition of
patient. Delay dosing in presence of elevated ciclosporin
blood levels. Monitor ciclosporin blood levels following
conversion. Dose recommendations – Rejection therapy.
Increased doses of tacrolimus, supplemental corticosteroid
therapy and introduction of short courses of mono-/poly-
clonal antibodies have all been used. If signs of toxicity are
noted the dose may need to reduced. For conversion to
PROGRAF, treatment should begin with the initial oral dose
recommended for primary immunosuppression. For conver-
sion of kidney and liver recipients from other immunosuppres-
sants to once daily ADVAGRAF, begin with the respective
initial dose recommended for rejection prophylaxis. In adult
heart transplant recipients converted to ADVAGRAF, an ini-
tial oral dose of 0.15 mg/kg/day should be administered once
daily in themorning. For other allografts, see SPC. Therapeu-
tic drug monitoring: Blood trough levels for ADVAGRAF
should be drawn approximately 24 hours post-dosing, just
prior to the next dose, for PROGRAF approximately 12 hours
post-dosing. Frequent trough level monitoring in the early
transplant period is recommended, with periodic monitoring
during maintenance therapy. Monitoring is also recom-
mended followingconversionfromPROGRAF toADVAGRAF,
dose adjustment, changes in the immunosuppressive regimen,
or co-administration of substances which may alter tacroli-
mus whole blood concentrations (see 'Warnings and Precau-
tions' and 'Interactions'). Adjustments to the ADVAGRAF
and PROGRAF dose regimen may take several days before
steady state is achieved. Most patients can be managed
successfully if tacrolimus blood concentrations are main-
tained below 20 ng/mL. In clinical practice, whole blood
trough levels have been 5-20 ng/mL in liver transplant re-
cipients and 10-20 ng/mL in kidney transplant recipients
early post-transplant, and 5-15 ng/mL during maintenance
therapy. Dose adjustments in specific populations: See SPC.
Contraindications: Hypersensitivity to tacrolimus or other
macrolides or any excipient. Warnings and Precautions:
Medication errors, including inadvertent, unintentional or
unsupervised substitution of immediate- or prolonged-
release tacrolimus formulations, have led to serious adverse
events, including graft rejection, or other side effects which
could be a consequence of either under- or over-exposure
to tacrolimus. Patients should be maintained on a single for-
mulation of tacrolimus with the corresponding daily dosing
regimen; alterations in formulation or regimen should only
take place under the close supervision of a transplant spe-
cialist. ADVAGRAF only limited experience in non-Caucasian
patients and those at elevated immunological risk.
ADVAGRAF is not recommended for use in children below
18 years due to limited data on safety and efficacy.
ADVAGRAF and PROGRAF: During the initial period
routinely monitor blood pressure, ECG, neurological and vi-
sual status, fasting blood glucose, electrolytes (particularly
potassium), liver and renal function tests, haematology pa-
rameters, coagulation values, and plasma protein determina-
tions; consider adjusting the immunosuppressive regimen if
clinically relevant changes are seen. Monitor tacrolimus
levels when co-administering strong inducers or inhibitors
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of CYP3A4. Herbal preparations, including those contain-
ing St. John’s Wort, should be avoided. Extra monitoring
of tacrolimus concentrations is recommended during epi-
sodes of diarrhoea. Avoid concomitant administration of
ciclosporin. Ventricular hypertrophy or hypertrophy of
the septum (reported as cardiomyopathy) have been re-
ported, occurring with tacrolimus blood trough concen-
trations much higher than the recommended maximum
tacrolimus blood trough concentrations levels. Other risk
factors for these conditions include pre-existing heart dis-
ease, corticosteroid usage, hypertension, renal or hepatic
dysfunction, infections, fluid overload, and oedema. Echo-
cardiography or ECG monitoring pre- and post-transplant
is advised in high-risk patients, and dose reduction or a
change of immunosuppressive agent should be considered
if abnormalities develop. Tacrolimus may prolong the
QT interval. Exercise caution in specific patients – see
SPC.. Patients are at increased risk of all opportunistic in-
fections including BK Virus associated nephropathy and
JC Virus associated progressive multifocal leukoencepha-
lopathy (PML); consider in patients with deteriorating re-
nal function or neurological symptoms. Patients have
been reported to develop posterior reversible encephalopa-
thy syndrome (PRES), if so radiological tests should be per-
formed. If PRES is diagnosed, control blood pressure and
seizures and immediately discontinue tacrolimus. Epstein
Barr Virus (EBV)-associated lymphoproliferative disorders
have been reported: concomitant use of other immunosup-
pressives such as antilymphocytic antibodies increase
the risk. EBV-Viral Capsid Antigen (VCA)- negative pa-
tients have been reported to have increased risk of lympho-
proliferative disorders; EBV-VCA serology should be
ascertained before starting tacrolimus treatment. During
treatment, careful monitoring with EBV-PCR is recom-
mended. Exposure to sunlight and UV light should be lim-
ited. The risk of secondary cancer is unknown. Dose
reduction may be necessary in patients with severe liver im-
pairment. Cases of pure red cell aplasia (PRCA) have been
reported in patients treated with tacrolimus. All patients
reported risk factors for PRCA such as parvovirus B19 infec-
tion, underlying disease or concomitant medications associ-
ated with PRCA. The printing ink used to mark
ADVAGRAF capsules contains soya lecithin. In patients
who are hypersensitive to peanut or soya, the risk and sever-
ity of hypersensitivity should be weighed against the benefit
of using ADVAGRAF. Capsules contain lactose. Interac-
tions: See SPC. Tacrolimus is metabolised by CYP3A4. Con-
comitant use of CYP3A4 inhibitors/inducers may increase/
decrease tacrolimus blood levels. Monitoring of tacrolimus
blood levels, renal function,side effects and QT prolongation
is strongly recommended during concomitant use. Interrupt/
adjust tacrolimus dose as necessary to maintain similar tacro-
limus exposure. Tacrolimus is a CYP3A4 inhibitor; concomi-
tant use with products metabolised by this enzyme may
affect themetabolism of these products.Pregnancy and lac-
tation: Tacrolimus can be considered in pregnant women
when there is no safer alternative. Cases of spontaneous
abortion have been reported. In case of in utero exposure,
monitoring of the newborn for the potential adverse events
of tacrolimus is recommended . Women should not breast
feed whilst receiving tacrolimus, see SPC. Undesirable ef-
fects: Infections: Cases of BK Virus associated nephropa-
thy, as well as cases of JC Virus associated PML have
been reported. Neoplasms: Increased risk of malignancies.
Malignant neoplasms including EBV-associated lymphopro-
liferative disorders and skin malignancies have been re-
ported. Cases of pure red cell aplasia have been reported.
Very Common (≥1/10): Hyperglycaemic conditions, diabe-
tes mellitus, hyperkalaemia, insomnia, tremor, headache, hy-
pertension, diarrhoea, nausea, renal impairment, infections,
liver function test abnormal, Common (≥1/100 to <1/10):
Haematological abnormalities, electrolytes decreased, fluid
overload, hyperuricaemia, appetite decreased, , metabolic
acidoses, lipid disorders, hypophosphataemia, anxiety
symptoms, mental disorders, confusion and disorientation,
depression, depressed mood, mood disorders and distur-
bances, nightmare, hallucination, seizures, disturbances in
consciousness, paraesthesias and dysaesthesias, periph-
eral neuropathies, dizziness, writing impaired, vision
blurred, photophobia, eye disorders, tinnitus, ischaemic
coronary artery disorders, tachycardia, haemorrhage,
thromboembolic and ischaemic events, vascular hypotensive
disorders, peripheral vascular disorders, dyspnoea, paren-
chymal lung disorders, pleural effusion, pharyngitis, cough,
nasal congestion and inflammations, gastrointestinal in-
flammatory conditions, gastrointestinal ulceration and per-
foration, gastrointestinal haemorrhages, stomatitis, ascites,
vomiting, gastrointestinal disorders, bile duct disorders,,
cholestasis and jaundice, hepatocellular damage and hepati-
tis, cholangitis, pruritus, rash, alopecias, acne, sweating
increased, arthralgia, muscle spasms, limb and back pain,
renal failure, oliguria, renal tubular necrosis, nephropa-
thy toxic, urinary abnormalities, bladder and urethral
symptoms, asthenic conditions, febrile disorders, pain,
discomfort, oedema, blood alkaline phosphatase in-
creased, weight increased, body temperature perception
disturbed, primary graft dysfunction. Uncommon (≥1/
1000 to <1/100): Coagulopathies, coagulation and bleeding
analyses abnormal, pancytopenia, hypoproteinaemia,
hyperphosphataemia, hypoglycaemia, dehydration, coma,
central nervous system haemorrhages and cerebrovascular
accidents, paralysis and paresis, encephalopathy, speech
and language disorders, amnesia, cataract, arrhythmias, car-
diac arrest, heart failures, cardiomyopathies, ECG
investigations abnormal, pulse investigations abnormal,
weight decrease, ventricular hypertrophy, palpitations,
infarction, deep venous thrombosis, shock, respiratory
failures, respiratory tract disorders, asthma, paralytic
ileus, peritonitis, acute and chronic pancreatitis, amy-
lase increased, blood lactate dehydrogenase increased,
gastrooesophageal reflux disease, impaired gastric emp-
tying, anuria, haemolytic uraemic syndrome, uterine
bleeding, psychotic disorder, multi-organ failure. Rare
(≥1/10,000 to <1/1000): Thrombotic thrombocytope-
nic purpura, blindness, neurosensory deafness, pericar-
dial effusion, acute respiratory distress syndrome,
subileus, pancreatic pseudocyst, hepatic artery throm-
bosis, venoocclusive liver disease, toxic epidermal
necrolysis (Lyell’s syndrome), mobility decreased, fall,
ulcer, chest tightness, thirst. Very rare (<1/10,000):
ECG abnormal, ECG QT prolonged, Torsades de
Pointes, hepatic failure, Stevens Johnson syndrome,
nephropathy, cystitis haemorrhagic. Not known: Pure
red cell aplasia, agranulocytosis, haemolytic anaemia.
Consult the SPC for complete information on side effects
and full prescribing information. Packs and prices:
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Country-specific. Legal Classification: POM. MA Num-
ber: PROGRAF: Country specific. ADVAGRAF: EU/1/
07/387/001-26. Date of Revision: November 2015. Fur-
ther information available from Astellas Pharma Europe
Ltd, 2000 Hillswood Drive, Chertsey, Surrey, KT16 0RS,
UK. ADVAGRAF and PROGRAF are registered trade-
marks. ADV/11/0030/EUc(4). Adverse events should
be reported. UK residents: Reporting form and
information can be found at www.mhra.gov.uk/
yellowcard. Adverse events should also be
reported to Astellas Pharma Ltd. on 0800 783
5018. Non-UK residents:Report adverse events to
Astellas Pharma Europe by email to safety-
eu@astellas.com, by facsimile to +31 (0)71-545
5208, or contact your local Astellas office (www.
astellas.eu/contact/locations/).
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